Tracers
647 of 647 agents. Sorted by how many syntheses are indexed.
All isotopes
Ac-225At-211Bi-213C-11Cu-61Cu-64Cu-67Er-169F-18Ga-67Ga-68Ho-166I-123I-124I-125I-131In-111Lu-177N-13Pb-203Pb-212Ra-223Re-188Sc-44Sc-47Sm-153Tb-161Tc-99mY-86Y-90Zr-89
| Agent | Isotope | Modality | Target / mechanism | Stage | Syntheses |
|---|---|---|---|---|---|
| [18F]FDG 2'-[18F]fluoro-2'-deoxy-D-glucose · 2-deoxy-2-[18F]fluoro-D-glucose · [18F]FDG | F-18 | PET | Glucose-transporter (GLUT)-mediated uptake and hexokinase phosphorylation with intracellular metabolic trapping (marker of glucose metabolism) | Approved | 164 |
| [68Ga]Ga-PSMA-11 [68Ga]Ga-PSMA-11 · [68Ga]Ga-PSMA-HBED-CC · [68Ga]Ga-PSMA11 | Ga-68 | PET | Prostate-specific membrane antigen (PSMA / glutamate carboxypeptidase II) | Approved | 108 |
| [177Lu]Lu-PSMA-617 177Lu-PSMA-617 · [177Lu]Lu-PSMA-617 · [177Lu]Lu-PSMA617 | Lu-177 | Therapy | Targets prostate-specific membrane antigen (PSMA); binding results in internalisation and delivery of β-radiation into PSMA-expressing cancer cells | approved | 96 |
| [68Ga]Ga-DOTATATE [68Ga]DOTATATE · [68Ga]Ga-DOTA-TATE · [68Ga]Ga-DOTATATE | Ga-68 | PET | Somatostatin receptor subtype 2 (SSTR2) | Approved | 94 |
| [68Ga]Ga-DOTA-TOC [68Ga]DOTATOC · [68Ga]Ga-DOTA-TOC · [68Ga]Ga-DOTATOC | Ga-68 | PET | Somatostatin receptor, predominantly subtype 2 (SSTR2) | Approved | 86 |
| [177Lu]Lu-DOTATATE 177Lu-DOTA-TATE · [177Lu]Lu-DOTA-TATE · [177Lu]Lu-DOTATATE | Lu-177 | Therapy | Targets somatostatin receptor subtype 2 (SSTR2) | approved (FDA-approved) | 77 |
| [68Ga]Ga-FAPI-46 [68Ga]FAPI-46 · [68Ga]Ga-FAPI-46 · [Ga-68]FAPI-46 | Ga-68 | PET | Fibroblast activation protein (FAP) | Clinical research | 77 |
| [68Ga]Ga-Pentixafor [68Ga]Ga-PentixaFor · [68Ga]PentixaFor · [Ga-68]Ga-PentixaFor | Ga-68 | PET | Chemokine receptor CXCR4, overexpressed in several haematologic and solid malignancies | Investigational (academic clinical studies) | 65 |
| [18F]FDOPA 6-[18F]fluoro-L-DOPA · [18F]dihydroxyphenylalanine · [18F]F-DOPA | F-18 | PET | System L (LAT1) amino-acid transport into cells; for dopaminergic imaging, subsequent decarboxylation by aromatic-L-amino-acid decarboxylase (AADC) | Approved | 49 |
| [68Ga]Ga-FAPI-04 [68Ga]Ga-FAPI-04 · [68Ga]Ga-FAPI-4 · [Ga-68]Ga-FAPI-04 | Ga-68 | PET | Fibroblast activation protein (FAP), a serine protease overexpressed on cancer-associated fibroblasts | — | 47 |
| [177Lu]Lu-PSMA-I&T [177Lu]Lu-PSMA-I&T | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | Investigational / clinical (academic use) | 39 |
| [123I]MIBG I-123 MIBG · I-123-MIBG · MIBG | I-123 | SPECT | Norepinephrine transporter-mediated uptake into sympathetic nerve terminals (noradrenergic/adrenergic system imaging) | — | 33 |
| [68Ga]Ga-PSMA-617 68Ga-PSMA-617 · [68Ga]Ga-PSMA-617 · [Ga-68]Ga-PSMA-617 | Ga-68 | PET | Prostate-specific membrane antigen (PSMA) inhibitor | Phase II clinical trial | 30 |
| [177Lu]Lu-DOTA-TOC [177Lu]Lu-DOTATOC · [Lu-177]Lu-DOTATOC · DOTA-TOC | Lu-177 | Therapy | Somatostatin receptor (SSTR) targeting agonist | — | 28 |
| [11C]PiB 2-(4-N-[11C]methylaminophenyl)-6-hydroxybenzothiazole · [11C]PIB · [C-11]PIB | C-11 | PET | Fibrillar amyloid-beta plaques | Clinical research | 25 |
| [68Ga]Ga-FAPI [68Ga]Ga-FAPI · [Ga-68]Ga-FAPI · FAPI | Ga-68 | PET | Targets fibroblast activation protein (FAP) overexpressed on cancer-associated fibroblasts | pilot clinical study | 25 |
| [18F]PSMA-1007 [18F]F-PSMA-1007 · [18F]PSMA-1007 · [F-18]PSMA-1007 | F-18 | PET | Prostate-specific membrane antigen (PSMA) | Clinical research | 24 |
| [18F]FET [18F]FET · [18F]fluoroethyltyrosine · [F-18]FET | F-18 | PET | System L amino-acid transport (LAT1) | Clinical research | 23 |
| [68Ga]Ga-NODAGA-exendin-4 [68Ga]Ga-NODAGA-Exendin-4 · [Ga-68]Ga-NODAGA-Exendin-4 · Exendin-4 | Ga-68 | PET | Glucagon-like peptide-1 receptor (GLP-1R), markedly overexpressed in benign insulinomas | — | 23 |
| [90Y]Y-ibritumomab ibritumomab tiuxetan · Zevalin · ibritumomab | Y-90 | Therapy | Binds CD20 antigen on B cells | FDA-approved | 23 |
| [18F]FLT 3'-deoxy-3'-[18F]fluorothymidine · [18F]FLT · [18F]Fluorothymidine | F-18 | PET | Phosphorylation by thymidine kinase 1 (TK1) and intracellular trapping (thymidine salvage pathway); marker of cell proliferation | Clinical research | 22 |
| [18F]FMISO 1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole · [18F]Fluoromisonidazole · [18F]FMISO | F-18 | PET | Bioreductive trapping: after cell entry the 2-nitroimidazole nitro group is reduced and, under hypoxia, binds irreversibly to intracellular macromolecules (re-oxidised and washed out under normoxia) | Clinical research | 22 |
| [225Ac]Ac-PSMA-617 PSMA-617 · [Ac-225]Ac-PSMA-617 · Ac-225-PSMA-617 | Ac-225 | Therapy | Targets prostate-specific membrane antigen (PSMA) | investigational | 21 |
| [131I]MIBG MIBG · [I-131]MIBG · I-131-MIBG | I-131 | Therapy | Norepinephrine transporter | approved | 19 |
| [90Y]Y-DOTA-TOC DOTATOC · Y-90-DOTATOC · DOTA-TOC | Y-90 | Therapy | Somatostatin receptor (SSTR) targeting | — | 19 |
| [131I]tositumomab tositumomab · Bexxar · Tositumomab | I-131 | Therapy | Targets CD20 antigen on B-cells; I-131 irradiates antibody-bound cells and surrounding tissue | approved | 18 |
| [18F]DCFPyL [18F]DCFPyL · [F-18]DCFPyL · DCFPyL | F-18 | PET | Prostate-specific membrane antigen (PSMA) | Approved | 16 |
| [177Lu]Lu-pentixather [177Lu]PentixaTher · [Lu-177]PentixaTher · Lu-177 Pentixather | Lu-177 | Therapy | Chemokine receptor CXCR4 | Investigational (first-in-human / early clinical) | 15 |
| [68Ga]Ga-RM2 [68Ga]Ga-RM2 · [Ga-68]Ga-RM2 · Ga-68 RM2 | Ga-68 | PET | Gastrin-releasing peptide receptor (GRPR); bombesin-based antagonist | Clinical research | 15 |
| [18F]SiTATE [18F]SiTATE · [F-18]SiTATE | F-18 | PET | Somatostatin receptor subtype 2 (SSTR2) | — | 14 |
| [223Ra]Ra-RaCl2 [Ra-223]RaCl2 | Ra-223 | Therapy | Calcium-mimetic alpha-emitter that localizes to bone metastases (bone-seeker) | approved | 14 |
| [11C]acetate [11C]Acetate · [C-11]Acetate · Acetate | C-11 | PET | Oxidative and fatty acid metabolism tracer; assesses oxidative metabolism and ketone body utilization pathway (acetate metabolism) | — | 13 |
| [11C]methionine [11C]MET · [11C]Methionine · [C-11]MET | C-11 | PET | L-type amino acid transporter 1 (LAT1), upregulated in gliomas and brain metastases | — | 13 |
| [18F]fallypride [18F]Fallypride · [F-18]Fallypride · Fallypride | F-18 | PET | Dopamine D2/D3 receptor ligand | — | 13 |
| [18F]NaF [18F]NaF · [F-18]NaF · F-18 NaF | F-18 | PET | Hydroxyapatite crystal surface of bone mineral — fluoride/hydroxyl ion exchange forming fluorapatite, reflecting osteoblastic activity and bone perfusion | Approved | 12 |
| [68Ga]Ga-DOTANOC [68Ga]Ga-DOTANOC · [Ga-68]Ga-DOTANOC · DOTA-NOC | Ga-68 | PET | Somatostatin receptors, primarily subtypes 2 and 5 (broader subtype profile than DOTATOC) | — | 12 |
| [18F]FAPI-74 [18F]FAPI-74 · [F-18]FAPI-74 · F-18 FAPI-74 | F-18 | PET | Fibroblast activation protein (FAP) | — | 11 |
| [18F]fluoroethylcholine [18F]fluoroethylcholine · [F-18]fluoroethylcholine · Fluoroethylcholine | F-18 | PET | — | — | 11 |
| [90Y]Y-microsphere [Y-90]microsphere · Y-90-Microsphere · Y-90-TARE | Y-90 | Therapy | — | approved | 11 |
| [153Sm]Sm-EDTMP Sm-153-EDTMP · [Sm-153]EDTMP | Sm-153 | Therapy | Bone hydroxyapatite (bone mineral matrix) | approved | 10 |
| [177Lu]Lu-DOTA-MGS5 [177Lu]Lu-DOTA-MGS5 · [Lu-177]Lu-DOTA-MGS5 | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK2R) targeting peptide analog | first therapeutic clinical trial initiation / first-in-patient therapy | 10 |
| [18F]AlF-FAPI-74 [18F]AlF-FAPI-74 · [F-18]AlF-FAPI-74 | F-18 | PET | Targets fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts in tumor stroma | — | 10 |
| [177Lu]Lu-FAPI-2286 [Lu-177]Lu-FAPI-2286 · Lu-177-FAPI-2286 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | — | 9 |
| [177Lu]Lu-FAPI-46 177Lu-FAPI-46 · [177Lu]Lu-FAPI-46 · [Lu-177]Lu-FAPI-46 | Lu-177 | Therapy | Targets fibroblast activation protein (FAP), expressed on cancer-associated fibroblasts and tumor cells | — | 9 |
| [177Lu]Lu-RM2 RM2 · [Lu-177]Lu-RM2 · rm2 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | — | 9 |
| [18F]FMZ [18F]Flumazenil · [18F]FMZ · [F-18]Flumazenil | F-18 | PET | Central benzodiazepine site of the GABA-A receptor | — | 9 |
| [18F]FSPG (S)-4-(3-[18F]fluoropropyl)-L-glutamic acid · [18F]FSPG · [F-18]FSPG | F-18 | PET | Cystine/glutamate antiporter (system xc-) | Clinical research | 9 |
| [18F]T807 [18F]AV-1451 · [18F]AV1451 · [18F]Flortaucipir | F-18 | PET | Aggregated tau protein (paired helical filaments) | Approved | 9 |
| [90Y]Y-pentixather Pentixather · pentixather · [Y-90]Pentixather | Y-90 | Therapy | CXCR4 (chemokine receptor-4) | — | 9 |
| [11C]choline [11C]Choline · [C-11]Choline · Choline | C-11 | PET | Choline kinase / choline transport, reflecting increased membrane-phospholipid synthesis in tumour cells | Approved | 8 |
| [123I]FP-CIT [123I]FP-CIT · [I-123]FP-CIT · FP-CIT | I-123 | SPECT | Dopamine transporter (DAT) at presynaptic nigrostriatal dopaminergic terminals | Approved | 8 |
| [177Lu]Lu-DOTA-LM3 [Lu-177]Lu-DOTA-LM3 · Lu-177-DOTA-LM3 | Lu-177 | Therapy | Somatostatin receptor subtype 2 (SST2) antagonist | first-in-human | 8 |
| [177Lu]Lu-LuPSMA-617 [Lu-177]LuPSMA-617 | Lu-177 | Therapy | Targets prostate-specific membrane antigen (PSMA) | approved | 8 |
| [18F]AV-45 [18F]AV-45 · [18F]florbetapir · [F-18]AV-45 | F-18 | PET | β-amyloid neuritic plaques (Kd approx. 3.7 nM in postmortem brain homogenates) | Approved | 8 |
| [18F]DPA-714 [18F]DPA-714 · [18F]DPA714 · [F-18]DPA-714 | F-18 | PET | 18-kDa translocator protein (TSPO), a marker of activated microglia/macrophages in neuroinflammation | — | 8 |
| [18F]FPEB [18F]FPEB · [F-18]FPEB · F-18 FPEB | F-18 | PET | Metabotropic glutamate receptor 5 (mGluR5) ligand | — | 8 |
| [225Ac]Ac-DOTATATE DOTATATE · [Ac-225]Ac-DOTATATE · DOTA-TATE | Ac-225 | Therapy | Somatostatin receptor 2 (SSTR2)-targeted alpha-particle therapy | Phase 1b/3 clinical trial | 8 |
| [68Ga]Ga-PSMA-I&T [68Ga]Ga-PSMA-I&T | Ga-68 | PET | Prostate-specific membrane antigen (PSMA) | — | 8 |
| [11C]raclopride [11C]Raclopride · [C-11]Raclopride · Raclopride | C-11 | PET | Dopamine D2/D3 receptor antagonist radiotracer | — | 7 |
| [177Lu]Lu-FAPI [177Lu]Lu-FAPI · [Lu-177]Lu-FAPI · FAPI | Lu-177 | Therapy | Fibroblast activation protein (FAP) targeting | — | 7 |
| [177Lu]Lu-PP-F11N [Lu-177]Lu-PP-F11N · PP-F11N · Lu-177-PP-F11N | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK2R/CCKBR) agonist | clinical trial (phase 0) | 7 |
| [18F]AlF-NOTA-FAPI-04 [18F]AlF-NOTA-FAPI-04 · [F-18]AlF-NOTA-FAPI-04 | F-18 | PET | Fibroblast activation protein (FAP) | — | 7 |
| [18F]FES [18F]FES · [18F]Fluoroestradiol · [F-18]FES | F-18 | PET | Estrogen receptor (ER) — binding affinity comparable to endogenous estradiol | Approved | 7 |
| [18F]SFB 4-[18F]fluorobenzoic acid · [18F]SFB · [F-18]SFB | F-18 | n/a | n/a | n/a | 7 |
| [18F]flutemetamol [18F]Flutemetamol · [F-18]Flutemetamol · Flutemetamol | F-18 | PET | β-amyloid aggregates | Approved | 7 |
| [211At]At-MABG [At-211]MABG · At-211-MABG | At-211 | Therapy | Targets neuroendocrine cells via norepinephrine transporter, similar to MIBG; alpha particle emitter with short path length effectively sterilizing microscopic residual disease | preclinical | 7 |
| [225Ac]Ac-PSMA-I&T PSMA I&T · [Ac-225]Ac-PSMA-I&T · PSMA-I&T | Ac-225 | Therapy | Targets prostate-specific membrane antigen (PSMA) | phase I clinical trial (planned/dose escalation) | 7 |
| [68Ga]Ga-FAP-2286 [68Ga]Ga-FAP-2286 · [Ga-68]Ga-FAP-2286 · FAP-2286 | Ga-68 | PET | Fibroblast activation protein (FAP) | — | 7 |
| [90Y]Y-DOTA-Phe1-Tyr3-octreotide [Y-90]DOTA-Phe1-Tyr3-octreotide · Y-90-DOTA-Phe1-Tyr3-Octreotide | Y-90 | Therapy | Somatostatin receptors (SSTR) | Phase I/II | 7 |
| [99mTc]Tc-PSMA-I&S [99mTc]Tc-PSMA-I&S | Tc-99m | SPECT | Targets prostate-specific membrane antigen (PSMA) | — | 7 |
| [11C](+)-PHNO [11C](+)-PHNO | C-11 | PET | Dopamine D2/D3 receptor agonist, D3-preferential | — | 6 |
| [177Lu]Lu-DOTA-JR11 [Lu-177]Lu-DOTA-JR11 · Lu-177-DOTA-JR11 | Lu-177 | Therapy | Somatostatin receptor 2 (SSTR2) antagonist | — | 6 |
| [18F]FBPA [18F]FBPA · [F-18]FBPA · FBPA | F-18 | PET | — | — | 6 |
| [18F]FHBG 9-(4-[18F]fluoro-3-hydroxymethylbutyl)guanine · [18F]FHBG · [F-18]FHBG | F-18 | PET | Herpes simplex virus type 1 thymidine kinase (HSV1-tk) / mutant HSV1-sr39tk enzyme — phosphorylation-dependent intracellular trapping | — | 6 |
| [18F]rhPSMA-7 [18F]Ga-rhPSMA-7 · [18F]rhPSMA-7 · [F-18]Ga-rhPSMA-7 | F-18 | PET | Prostate-specific membrane antigen (PSMA) targeting ligand | clinical trial | 6 |
| [212Pb]Pb-PSC-PEG2-TOC [212Pb]Pb-PSC-PEG2-TOC · [Pb-212]Pb-PSC-PEG2-TOC | Pb-212 | Therapy | Targets somatostatin receptor subtype 2 (SSTR2) | — | 6 |
| [64Cu]Cu-DOTATATE [64Cu]Cu-DOTATATE · copper Cu 64 dotatate | Cu-64 | PET | Somatostatin receptor subtype 2 (SSTR2) | Approved | 6 |
| [68Ga]Ga-BPAMD [68Ga]Ga-BPAMD · [Ga-68]Ga-BPAMD · BPAMD | Ga-68 | PET | Bisphosphonate binding to bone mineral (hydroxyapatite) | — | 6 |
| [68Ga]Ga-citrate [68Ga]Ga-Citrate · [Ga-68]Ga-Citrate · Citrate | Ga-68 | PET | — | — | 6 |
| [90Y]Y-FAPI-46 [90Y]Y-FAPI-46 · [Y-90]Y-FAPI-46 | Y-90 | Therapy | Fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts | early-stage clinical evidence / investigational | 6 |
| [123I]iodoamphetamine [123I]iodoamphetamine · [I-123]iodoamphetamine | I-123 | SPECT | — | — | 5 |
| [13N]Ammonia [13N]Ammonia · [N-13]Ammonia | N-13 | PET | — | — | 5 |
| [177Lu]Lu-AMTG [Lu-177]Lu-AMTG · Lu-177-AMTG | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | first-in-human | 5 |
| [177Lu]Lu-DOTA-trastuzumab [Lu-177]Lu-DOTA-Trastuzumab · [Lu-177]Lu-DOTA-trastuzumab · Lu-177-DOTA-trastuzumab | Lu-177 | Therapy | Targets HER2 (human epidermal growth factor receptor 2) via trastuzumab antibody binding | clinical evaluation | 5 |
| [177Lu]Lu-FAPI-04 [177Lu]Lu-FAPI-04 · [Lu-177]Lu-FAPI-04 · FAPI-04 | Lu-177 | Therapy | — | — | 5 |
| [177Lu]Lu-oxodotreotide Lu-177-Oxodotreotide · [Lu-177]Lu-oxodotreotide | Lu-177 | Therapy | — | — | 5 |
| [18F]DAA1106 [18F]DAA1106 · [F-18]DAA1106 | F-18 | PET | translocator protein (18 kDa, TSPO) | preclinical | 5 |
| [18F]FE-PE2I [18F]FE-PE2I · [F-18]FE-PE2I · FE-PE2I | F-18 | PET | Dopamine transporter (DAT) | — | 5 |
| [18F]FETrp [18F]FETrp · [F-18]FETrp · F-18 FETrp | F-18 | PET | Amino-acid transporters and the IDO-mediated kynurenine pathway of tryptophan metabolism | Research | 5 |
| [18F]FMAU [18F]FMAU · [F-18]FMAU · FMAU | F-18 | PET | Thymidine kinase-mediated phosphorylation and incorporation into DNA (marker of DNA synthesis) | — | 5 |
| [18F]JK-PSMA-7 (((S)-1-carboxy-5-(6-([18F]fluoro)-2-methoxynicotinamido)pentyl)carbamoyl)-L-glutamic acid · [18F]JK-PSMA-7 · [18F]JK-PSMA7 | F-18 | PET | Prostate-specific membrane antigen (PSMA) inhibitor | — | 5 |
| [18F]fluspidine [18F]fluspidine | F-18 | PET | σ1 receptor ligand | first-in-human / first clinical trial | 5 |
| [212Pb]Pb-212-TCMC-trastuzumab Pb-212-TCMC-trastuzumab | Pb-212 | Therapy | HER2-targeting via trastuzumab antibody delivering alpha-emitting 212Pb | Phase I clinical trial (first-in-human) | 5 |
| [225Ac]Ac-DOTA-trastuzumab [Ac-225]Ac-DOTA-trastuzumab · [Ac-225]Ac-DOTA-Trastuzumab · Ac-225-DOTA-trastuzumab | Ac-225 | Therapy | HER2 receptor targeting via trastuzumab antibody | — | 5 |
| [68Ga]Ga-DOTA-CCK-66 DOTA-CCK-66 · Ga-68 DOTA-CCK-66 · Ga-68-DOTA-CCK-66 | Ga-68 | PET | Cholecystokinin-2 receptor (CCK2R) targeting peptide | proof-of-concept clinical investigation | 5 |
| [68Ga]GaCl3 [68Ga]GaCl3 · [Ga-68]GaCl3 · gallium-68 chloride | Ga-68 | PET | n/a | n/a | 5 |
| [111In]In-PSMA-617 [111In]In-PSMA-617 · [In-111]In-PSMA-617 · PSMA-617 | In-111 | SPECT | Prostate-specific membrane antigen (PSMA) | Research | 4 |
| [11C]DASB [11C]DASB · [C-11]DASB · DASB | C-11 | PET | Serotonin transporter (SERT) | — | 4 |
| [11C]L-deprenyl-D2 [11C]L-deprenyl-D2 · [C-11]L-deprenyl-D2 | C-11 | PET | Monoamine oxidase-B (MAO-B) | — | 4 |
| [11C]UCB-J [11C]UCB-J · [C-11]UCB-J · UCB-J | C-11 | PET | Targets synaptic vesicle glycoprotein 2A (SV2A) to visualize synaptic density | — | 4 |
| [11C]ibrutinib [11C]Ibrutinib · [C-11]Ibrutinib | C-11 | PET | Bruton's tyrosine kinase (BTK) | — | 4 |
| [161Tb]Tb-DOTATATE DOTATATE · [Tb-161]Tb-DOTATATE · DOTA-TATE | Tb-161 | Therapy | Somatostatin receptor 2 (SSTR2) agonist | — | 4 |
| [161Tb]Tb-crown [Tb-161]Tb-crown | Tb-161 | Therapy | — | — | 4 |
| [177Lu]Lu-CP04 [177Lu]Lu-CP04 · [Lu-177]Lu-CP04 | Lu-177 | Therapy | CCK-2 receptor (CCK2R) targeting | — | 4 |
| [177Lu]Lu-FAP-2286 [Lu-177]Lu-FAP-2286 · FAP-2286 · Lu-177-FAP-2286 | Lu-177 | Therapy | Targets fibroblast activation protein (FAP) | first-in-human | 4 |
| [177Lu]Lu-HA-DOTATATE [Lu-177]Lu-HA-DOTATATE · Lu-177-HA-DOTATATE | Lu-177 | Therapy | — | — | 4 |
| [177Lu]Lu-PSMA-ALB-56 [Lu-177]Lu-PSMA-ALB-56 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) radioligand with albumin-binding properties to increase tumor uptake | — | 4 |
| [18F]AmBF3-TATE [18F]AMBF3-TATE · [F-18]AMBF3-TATE | F-18 | PET | Somatostatin receptor subtype 2 (SSTR2) agonist binding | preclinical study | 4 |
| [18F]FAZA [18F]FAZA · [18F]fluoroazomycinarabinoside · [F-18]FAZA | F-18 | PET | Hypoxic cells — bioreductive (nitroreductase-mediated) trapping under low oxygen tension | — | 4 |
| [18F]FEPPA [18F]FEPPA · [F-18]FEPPA · FEPPA | F-18 | PET | 18-kDa translocator protein (TSPO), microglial-activation marker | — | 4 |
| [18F]FPIA 18F-pivalate · [18F]Fluoropivalate · [18F]fluoropivalic acid | F-18 | PET | Short-chain fatty acid uptake and metabolism | Clinical research | 4 |
| [18F]FTHA [18F]fluoro-6-thia-heptadecanoic · [18F]FTHA · [F-18]fluoro-6-thia-heptadecanoic | F-18 | PET | — | — | 4 |
| [18F]SynVesT-1 [18F]MNI-1126 · [18F]SDM-8 · [18F]SynVesT-1 | F-18 | PET | Binds synaptic vesicle glycoprotein 2A (SV2A), a 12-pass transmembrane protein in presynaptic vesicles | — | 4 |
| [18F]TFB [18F]BF4 · [18F]BF4- · [18F]Tetrafluoroborate | F-18 | PET | Sodium/iodide symporter (NIS) substrate | Clinical research | 4 |
| [18F]THK5351 [18F]THK-5351 · [18F]THK5351 · [F-18]THK-5351 | F-18 | PET | Aggregated tau (neurofibrillary tangles); substantial off-target binding to monoamine oxidase-B (MAO-B) | Research | 4 |
| [212Pb]Pb-MC1L [Pb-212]Pb-MC1L | Pb-212 | Therapy | Melanocortin 1 receptor (MC1R) | — | 4 |
| [212Pb]Pb-TCMC-chOI-1 [Pb-212]Pb-TCMC-chOI-1 · Pb-212-TCMC-chOI-1 | Pb-212 | Therapy | Targets PTK7 (protein tyrosine kinase 7) expressed on tumor cells via chimeric anti-PTK7 antibody chOI-1, delivering alpha-emitting 212Pb | preclinical study | 4 |
| [225Ac]Ac-DOTA-YS5 [Ac-225]DOTA-YS5 · [Ac-225]Ac-DOTA-YS5 · Ac-225-DOTA-YS5 | Ac-225 | Therapy | Targets a tumor-selective CD46 epitope via the YS5 antibody | preclinical study | 4 |
| [225Ac]Ac-Macropa-PEG4-YS5 [Ac-225]Macropa-PEG4-YS5 · Ac-225-Macropa-PEG4-YS5 | Ac-225 | Therapy | CD46-targeted alpha therapy using antibody YS5 | — | 4 |
| [64Cu]Cu-sartate Cu-64 SARTATE · SARTATE | Cu-64 | PET | Somatostatin receptor (SSTR) binding via octreotate peptide | first-in-human | 4 |
| [68Ga]Ga-OncoFAP-DOTAGA [68Ga]Ga-OncoFAP-DOTAGA · [Ga-68]Ga-OncoFAP-DOTAGA | Ga-68 | PET | FAP | Research | 4 |
| [68Ga]Ga-TRAP-(RGD)3 Ga-68 TRAP-(RGD)3 · Ga-68-TRAP-(RGD)3 · TRAP-(RGD)3 | Ga-68 | PET | αvβ3-integrin binding via RGD peptide motif | — | 4 |
| [89Zr]Zr-DFO-girentuximab [89Zr]Zr-DFO-girentuximab | Zr-89 | PET | Targets Carbonic Anhydrase IX (CA-IX) antigen | clinical proof-of-concept / prospective pilot study | 4 |
| [90Y]Y-DOTATATE DOTATATE · DOTA-TATE · dotatate | Y-90 | Therapy | Somatostatin receptor (SSTR) binding | — | 4 |
| 16-[18F]fluoro-4-thia-palmitic acid 16-[18F]fluoro-4-thia-palmitic acid | F-18 | PET | — | — | 3 |
| [11C]AMT [11C]AMT · [C-11]AMT · AMT | C-11 | PET | Tryptophan hydroxylase (serotonin synthesis pathway) / tryptophan metabolism | — | 3 |
| [11C]AZ13198083 [11C]AZ13198083 · [C-11]AZ13198083 | C-11 | PET | Histamine type-3 receptor (H3R) | — | 3 |
| [11C]PBR28 [11C]PBR28 · [C-11]PBR28 · C-11 PBR28 | C-11 | PET | Binds translocator protein (TSPO, 18 kDa), a marker of microglial activation | — | 3 |
| [11C]acetoacetate [11C]Acetoacetate · [C-11]Acetoacetate | C-11 | PET | — | — | 3 |
| [11C]evobrutinib [11C]Evobrutinib · [C-11]Evobrutinib | C-11 | PET | Bruton's tyrosine kinase inhibitor | — | 3 |
| [131I]ICF01012 [I-131]ICF01012 | I-131 | Therapy | Binds melanin in pigmented melanoma cells | phase I clinical trial (first-in-human) | 3 |
| [131I]iodine [I-131]iodine · [I-131]Iodine | I-131 | Therapy | Sodium iodide symporter (NIS)-mediated iodide uptake following gene transfer | — | 3 |
| [161Tb]Tb-DOTA-LM3 [Tb-161]Tb-DOTA-LM3 | Tb-161 | Therapy | Somatostatin receptor (SSTR) antagonist | Phase 0 clinical study | 3 |
| [166Ho]Ho-166-PLLA Ho-166-PLLA | Ho-166 | Therapy | Selective internal radiotherapy (transarterial radioembolization) via microsphere embolization delivering beta radiation to liver tumors | — | 3 |
| [177Lu]Lu-AMBA [Lu-177]Lu-AMBA | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist/agonist ligand | — | 3 |
| [177Lu]Lu-DOTA-4AH29 [Lu-177]Lu-DOTA-4AH29 | Lu-177 | Therapy | Fibroblast activation protein alpha (FAP) targeting via single-domain antibody 4AH29 | — | 3 |
| [177Lu]Lu-DOTA-PP-F11N [177Lu]Lu-DOTA-PP-F11N · [Lu-177]Lu-DOTA-PP-F11N | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK2R) | — | 3 |
| [177Lu]Lu-J591 Lu-177-J591 · [Lu-177]Lu-J591 | Lu-177 | Therapy | Targets prostate-specific membrane antigen (PSMA) | investigational | 3 |
| [177Lu]Lu-P17-087 [177Lu]Lu-P17-087 · [Lu-177]Lu-P17-087 | Lu-177 | Therapy | Prostate specific membrane antigen (PSMA) | investigational | 3 |
| [177Lu]Lu-P17-088 [177Lu]Lu-P17-088 · [Lu-177]Lu-P17-088 | Lu-177 | Therapy | Prostate specific membrane antigen (PSMA) | clinical investigation | 3 |
| [177Lu]Lu-vipivotide [Lu-177]Lu-vipivotide | Lu-177 | Therapy | — | — | 3 |
| [188Re]Re-188-HDD/lipiodol Re-188-HDD/lipiodol · Re-188-HDD/Lipiodol | Re-188 | Therapy | — | — | 3 |
| [188Re]Re-MAG3 [Re-188]MAG3 · Re-188-MAG3 | Re-188 | Therapy | — | — | 3 |
| [18F]AlF-NOTA-octreotide [18F]AlF-NOTA-Octreotide · [F-18]AlF-NOTA-Octreotide | F-18 | PET | Binds somatostatin receptor subtype 2 (SSTR2) | — | 3 |
| [18F]AlF-P16-093 [18F]AlF-P16-093 · [F-18]AlF-P16-093 | F-18 | PET | Prostate specific membrane antigen (PSMA) | — | 3 |
| [18F]Dolutegravir [18F]Dolutegravir · [F-18]Dolutegravir | F-18 | PET | — | first-in-human (suitable for human applications) | 3 |
| [18F]F-PRGD2 [18F]F-PRGD2 · [F-18]F-PRGD2 | F-18 | PET | αvβ3 integrin expression | first-in-human | 3 |
| [18F]FACBC [18F]FACBC · [F-18]FACBC · anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid | F-18 | PET | Amino acid transporters ASCT2 and LAT1, upregulated on prostate-cancer cells | Approved | 3 |
| [18F]FAPI-42 [18F]FAPI-42 · [F-18]FAPI-42 | F-18 | PET | Fibroblast activation protein (FAP) inhibitor targeting FAP-expressing cells | — | 3 |
| [18F]FBA 4-[18F]fluorobenzaldehyde · [18F]FBA · [F-18]FBA | F-18 | n/a | n/a | n/a | 3 |
| [18F]FBEM 4-[18F]fluorobenzamido-N-ethylamino-maleimide · [18F]FBEM · [F-18]FBEM | F-18 | PET | Thiol-reactive (maleimide) 18F-prosthetic group; site-specific conjugation to free cysteine thiols; no biological target | Research | 3 |
| [18F]FET-bAG-TOCA [18F]FET-bAG-TOCA · [F-18]FET-bAG-TOCA · FET-bAG-TOCA | F-18 | PET | SSTR2 | Research | 3 |
| [18F]FMeNER-D2 [18F]FMeNER-D2 · [F-18]FMeNER-D2 | F-18 | PET | Norepinephrine transporter (NET) | — | 3 |
| [18F]FP-CIT [18F]FP-CIT · [F-18]FP-CIT · F-18 FP-CIT | F-18 | PET | Dopamine transporter (DAT) - striatal dopaminergic terminal density | — | 3 |
| [18F]FSW-100 [18F]FSW-100 · [F-18]FSW-100 | F-18 | PET | Histone deacetylase 6 (HDAC6) | — | 3 |
| [18F]FTYR 2-[18F]fluoro-L-tyrosine · [18F]F-Tyr · [18F]FTYR | F-18 | PET | Amino-acid (system L) transport; incorporation into protein synthesis | Research | 3 |
| [18F]GE-180 [18F]GE-180 · [18F]GE180 · [F-18]GE-180 | F-18 | PET | TSPO (18 kDa translocator protein) | Clinical research | 3 |
| [18F]ICMT-11 [18F]ICMT-11 · [F-18]ICMT-11 · F-18 ICMT-11 | F-18 | PET | Activated caspase-3 (apoptosis); isatin-5-sulfonamide caspase-3 inhibitor | Clinical research | 3 |
| [18F]LBT999 [18F]LBT-999 · [18F]LBT999 · [F-18]LBT-999 | F-18 | PET | dopamine transporter (DAT) | Phase III clinical trial | 3 |
| [18F]PBR111 [18F]PBR111 · [F-18]PBR111 | F-18 | PET | 18 kDa translocator protein (TSPO) | — | 3 |
| [18F]fluoromannitol [18F]Fluoromannitol · [18F]FMtl · [F-18]Fluoromannitol | F-18 | PET | Pathogen-specific mannitol transporter, selectively taken up by Gram-positive and Gram-negative bacteria | — | 3 |
| [211At]At-astatobenzoate [At-211]astatobenzoate | At-211 | Therapy | — | — | 3 |
| [211At]At-meta-astatobenzylguanidine [At-211]meta-astatobenzylguanidine | At-211 | Therapy | — | first-in-human clinical trial | 3 |
| [212Pb]Pb-DOTAMTATE [Pb-212]Pb-DOTAMTATE · Pb-212-DOTAMTATE | Pb-212 | Therapy | Somatostatin receptor type 2 (SSTR2)-targeting octreotate analogue | preclinical | 3 |
| [225Ac]Ac-225-PRIT Ac-225-PRIT | Ac-225 | Therapy | Pretargeting via bispecific anti-HER2/anti-DOTA antibody (or anti-GPA33/anti-DOTA antibody) that binds tumor antigen then captures 225Ac-DOTA hapten | preclinical study | 3 |
| [61Cu]CuCl2 [61Cu]CuCl2 · [Cu-61]CuCl2 · copper-61 chloride | Cu-61 | PET | n/a | Research | 3 |
| [68Ga]Ga-DOTA-D-Phe-Tyr3-octreotide DOTA-D-Phe-Tyr3-octreotide · Ga-68 DOTA-D-Phe-Tyr3-octreotide · Ga-68-DOTA-D-Phe-Tyr3-octreotide | Ga-68 | PET | Somatostatin receptor (SSTR) | approved/clinical use | 3 |
| [68Ga]Ga-DOTA-exendin-4 [68Ga]Ga-DOTA-exendin-4 · [Ga-68]Ga-DOTA-exendin-4 | Ga-68 | PET | GLP-1 receptor (GLP-1R) | — | 3 |
| [90Y]Y-PSMA-617 PSMA-617 · Pluvicto | Y-90 | Therapy | — | — | 3 |
| [99mTc]Tc-TcO4 [99mTc]NaTcO4 · [99mTc]TcO4 · [Tc-99m]NaTcO4 | Tc-99m | SPECT | — | — | 3 |
| [111In]In-RM2 [111In]In-RM2 | In-111 | SPECT | Gastrin-releasing peptide receptor (GRPR) | Research | 2 |
| [111In]pb12 [In-111]In-pb12 | In-111 | Therapy | Human Y1 receptor (hY1R), a G protein-coupled receptor overexpressed on cancer cells | Reported once | 2 |
| [11C]6-bromopurine [11C]6-bromopurine · [C-11]6-bromopurine | C-11 | PET | Measures multidrug resistance-associated protein 1 (MRP1) transport activity | preclinical (non-clinical toxicity study and human dosimetry estimates, prepared to advance to clinical use) | 2 |
| [11C]L-glutamine [11C]L-Glutamine · [C-11]L-Glutamine | C-11 | PET | Glutamine utilization/transport as carbon source for cancer cell metabolism (glutaminolysis) | — | 2 |
| [11C]LY2795050 [11C]LY2795050 · [C-11]LY2795050 | C-11 | PET | KOR antagonist | — | 2 |
| [11C]erlotinib [11C]erlotinib · [C-11]erlotinib | C-11 | PET | Epidermal growth factor receptor (EGFR) | — | 2 |
| [131I]I-GMIB-4AH29 [I-131]I-GMIB-4AH29 | I-131 | Therapy | — | — | 2 |
| [161Tb]Tb-AMTG [Tb-161]Tb-AMTG | Tb-161 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | preclinical study | 2 |
| [161Tb]Tb-RM2 RM2 · rm2 · Rm2 | Tb-161 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | preclinical study | 2 |
| [161Tb]Tb-TbCl3 [Tb-161]TbCl3 | Tb-161 | Therapy | — | — | 2 |
| [177Lu]Lu-6R-RedFol-1 [Lu-177]Lu-6R-RedFol-1 | Lu-177 | Therapy | Folate receptor (FR) targeting | Reported once | 2 |
| [177Lu]Lu-AKIR001 [Lu-177]Lu-AKIR001 | Lu-177 | Therapy | CD44v6-targeted antibody radiotherapeutic | phase 1 clinical trial | 2 |
| [177Lu]Lu-BPAMD [Lu-177]Lu-BPAMD | Lu-177 | Therapy | Bone-seeking bisphosphonate with hydroxyapatite affinity for skeletal targeting | — | 2 |
| [177Lu]Lu-CTT2001 CTT2001 · Lu-177 CTT2001 · Lu-177-CTT2001 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) irreversible phosphoramidate inhibitor | first-in-human | 2 |
| [177Lu]Lu-DOTA-CCK-66 [Lu-177]Lu-DOTA-CCK-66 | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK-2R) | preclinical study | 2 |
| [177Lu]Lu-DOTA-DV1-K-DV3 [Lu-177]Lu-DOTA-DV1-K-DV3 · [Lu-177]Lu-DOTA-DV1-k-(DV3 | Lu-177 | Therapy | CXCR4 (C-X-C chemokine receptor 4) antagonist/binder | — | 2 |
| [177Lu]Lu-DOTA-Rituximab [Lu-177]Lu-DOTA-Rituximab · [Lu-177]Lu-DOTA-rituximab · Lu-177-DOTA-Rituximab | Lu-177 | Therapy | CD20 antigen on B-cells (via rituximab antibody) | — | 2 |
| [177Lu]Lu-DOTA-r-a-ABA-CPCR4 [Lu-177]DOTA-r-a-ABA-CPCR4 | Lu-177 | Therapy | CXCR4 receptor targeting ligand | — | 2 |
| [177Lu]Lu-DOTA-r-a-ABA-iodoCPCR4 [177Lu]DOTA-r-a-ABA-iodoCPCR4 · [Lu-177]DOTA-r-a-ABA-iodoCPCR4 | Lu-177 | Therapy | CXCR4-targeting ligand | preclinical study | 2 |
| [177Lu]Lu-Gemini [Lu-177]Lu-Gemini | Lu-177 | Therapy | Anti-DOTA bispecific antibody (anti-GPA33/anti-DOTA IgG-scFv BsAb) pretargeting for DOTA-PRIT, binding GPA33 tumor antigen indirectly via BsAb | — | 2 |
| [177Lu]Lu-Ibu-DAB-PSMA [Lu-177]Lu-Ibu-DAB-PSMA | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) targeting radioligand with albumin-binding moiety | preclinical study | 2 |
| [177Lu]Lu-NeoB [Lu-177]Lu-NeoB · [Lu-177]NeoB | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist/binder | phase I/IIa clinical trial (first-in-human) | 2 |
| [177Lu]Lu-girentuximab [Lu-177]Lu-girentuximab | Lu-177 | Therapy | Carbonic Anhydrase IX (CA-IX) | — | 2 |
| [177Lu]Lu-pepa-pic2-C-Hex-KuE [Lu-177]Lu-pepa-pic2-C-Hex-KuE | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 2 |
| [177Lu]Lu-rhPSMA-7 [Lu-177]Lu-rhPSMA-7 · rhPSMA-7.3 | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | — | 2 |
| [188Re]Re-188-DTPA-deoxyglucose Re-188-DTPA-deoxyglucose | Re-188 | Therapy | — | — | 2 |
| [188Re]Re-ReO4 [Re-188]ReO4 | Re-188 | Therapy | — | — | 2 |
| [188Re]Re-perrhenate [Re-188]perrhenate | Re-188 | Therapy | — | — | 2 |
| [188Re]Re-tricarbonyl(cyclopentadienylcarbonate)rhenium [Re-188]tricarbonyl(cyclopentadienylcarbonate)rhenium | Re-188 | Therapy | — | preclinical | 2 |
| [18F]6-O-desmethyl-diprenorphine [18F]6-O-desmethyl-diprenorphine · [F-18]6-O-desmethyl-diprenorphine | F-18 | PET | μ-opioid receptors | — | 2 |
| [18F]AF78 [18F]AF78 · [F-18]AF78 | F-18 | PET | Norepinephrine transporter (NET) | first-in-human | 2 |
| [18F]AlF-3p-C-NETA-TATE [18F]AlF-3p-C-NETA-TATE · [F-18]AlF-3p-C-NETA-TATE | F-18 | PET | Somatostatin receptor targeting (TATE/octreotate analogue) | preclinical study | 2 |
| [18F]AlF-LNC1007 [F-18]AlF-LNC1007 | F-18 | Therapy | Dual-targeting of fibroblast activation protein (FAP) and integrin αvβ3 | Reported once | 2 |
| [18F]AlF-NOTA-RD2 [18F]AlF-NOTA-RD2 · [F-18]AlF-NOTA-RD2 | F-18 | PET | — | — | 2 |
| [18F]DK222 [18F]DK222 · [F-18]DK222 · DK222 | F-18 | PET | Programmed death-ligand 1 (PD-L1); peptide binder | Research | 2 |
| [18F]F-PSMA-617-NODA [18F]F-PSMA-617-NODA · [F-18]F-PSMA-617-NODA | F-18 | PET | PSMA (prostate-specific membrane antigen) targeting ligand | — | 2 |
| [18F]F-PSMA-617-RESCA [18F]F-PSMA-617-RESCA · [F-18]F-PSMA-617-RESCA | F-18 | PET | PSMA (prostate-specific membrane antigen) | — | 2 |
| [18F]FB(ePEG12)12-exendin-4 [18F]FB(ePEG12)12-exendin-4 · [F-18]FB(ePEG12)12-exendin-4 | F-18 | PET | GLP-1 receptor (GLP-1R) | Phase 1 clinical study (first-in-human) | 2 |
| [18F]FB-HER2 [18F]FB-HER2 · [F-18]FB-HER2 | F-18 | PET | Human Epidermal Growth Factor Receptor 2 (HER2) | — | 2 |
| [18F]FBnTP [18F]FBnTP · [F-18]FBnTP | F-18 | PET | Mitochondrial membrane potential sensor; cellular uptake correlated with mitochondrial oxidative phosphorylation | — | 2 |
| [18F]FCH [18F]choline · [18F]FCH · [18F]fluorocholine | F-18 | PET | Choline kinase / choline transport (same mechanism class as 11C-choline) | — | 2 |
| [18F]FDHT F-18 FDHT · F-18-FDHT · FDHT | F-18 | PET | Androgen receptor (AR) | — | 2 |
| [18F]FEAU [18F]FEAU · [F-18]FEAU | F-18 | PET | Substrate for HSV1-tk/sr39tk enzyme, trapped intracellularly after phosphorylation, enabling reporter gene imaging | — | 2 |
| [18F]FEDAA1106 [18F]FEDAA1106 · [F-18]FEDAA1106 | F-18 | PET | 18 kDa translocator protein (TSPO) | investigational | 2 |
| [18F]FGln [18F]FGln · [18F]fluoroglutamine · [F-18]FGln | F-18 | PET | — | — | 2 |
| [18F]FMPEP-d2 [18F]FMPEP-d2 · [F-18]FMPEP-d2 | F-18 | PET | CB1R inverse agonist | — | 2 |
| [18F]FP-TZTP [18F]FP-TZTP · [F-18]FP-TZTP | F-18 | PET | Muscarinic acetylcholine receptor subtype 2 (M2) | — | 2 |
| [18F]Florbetaben [18F]Florbetaben · [F-18]Florbetaben · Florbetaben | F-18 | PET | Fibrillar amyloid-β plaque | approved | 2 |
| [18F]GE-179 [18F]GE-179 · [18F]GE179 · [F-18]GE-179 | F-18 | PET | Open / activated NMDA-receptor ion channel (intra-channel PCP binding site) | Research | 2 |
| [18F]JNJ64413739 F-18 JNJ64413739 · F-18-JNJ64413739 · JNJ64413739 | F-18 | PET | Purinergic ion channel receptor 7 (P2X7R) | — | 2 |
| [18F]MC225 [18F]MC225 · [F-18]MC225 | F-18 | PET | P-glycoprotein (P-gp) function at the blood-brain barrier | — | 2 |
| [18F]MK-6240 [18F]MK-6240 · [18F]MK6240 · [F-18]MK-6240 | F-18 | PET | Aggregated tau (neurofibrillary tangles) | Approved | 2 |
| [18F]NAV4694 [18F]AZD4694 · [18F]NAV4694 · [F-18]AZD4694 | F-18 | PET | Amyloid-beta (Aβ) PET tracer | — | 2 |
| [18F]P10A-1910 [18F]P10A-1910 · [F-18]P10A-1910 | F-18 | PET | Phosphodiesterase 10A (PDE10A) | first-in-human | 2 |
| [18F]PARPi [18F]PARPi · [F-18]PARPi | F-18 | PET | — | clinical trials | 2 |
| [18F]PBR102 [18F]PBR102 · [F-18]PBR102 | F-18 | PET | 18-kDa translocator protein (TSPO) / peripheral benzodiazepine receptor (PBR) | preclinical | 2 |
| [18F]cGBP4F [18F]cGBP4F · [F-18]cGBP4F | F-18 | PET | Ligand for the α2δ subunit of voltage-dependent calcium channels | — | 2 |
| [18F]d2-tosylate [18F]d2-tosylate · [F-18]d2-tosylate | F-18 | PET | — | — | 2 |
| [18F]fludarabine [18F]Fludarabine · [F-18]Fludarabine | F-18 | PET | — | first-in-human | 2 |
| [18F]fluoro-2-deoxy-D-galactose [18F]fluoro-2-deoxy-D-galactose · [F-18]fluoro-2-deoxy-D-galactose | F-18 | PET | — | — | 2 |
| [18F]fluoroacetate [18F]fluoroacetate · [F-18]fluoroacetate · Fluoroacetate | F-18 | PET | Aconitase (TCA cycle enzyme) / fatty acid and glial oxidative metabolism | — | 2 |
| [18F]tGBP4F [18F]tGBP4F · [F-18]tGBP4F | F-18 | PET | Ligand for the α2δ subunit of voltage-dependent calcium channels | — | 2 |
| [211At]At-211-AMT At-211-AMT | At-211 | Therapy | — | — | 2 |
| [211At]At-211-BC8-B10 At-211-BC8-B10 | At-211 | Therapy | CD45 | phase I/II clinical trial | 2 |
| [211At]At-211-MX35 At-211-MX35 | At-211 | Therapy | Targets NaPi2b cell surface glycoprotein on ovarian cancer cells | — | 2 |
| [211At]At-NaAt [At-211]NaAt | At-211 | Therapy | — | investigational product for investigator-initiated clinical trial | 2 |
| [211At]At-PSMA-5 [At-211]PSMA-5 | At-211 | Therapy | Targets prostate-specific membrane antigen (PSMA), overexpressed in metastatic castration-resistant prostate cancer | first-in-human / preclinical (preparation for first-in-human clinical trial) | 2 |
| [212Pb]Pb-AB001 [Pb-212]Pb-AB001 | Pb-212 | Therapy | PSMA-targeting alpha-emitting radioligand | — | 2 |
| [212Pb]Pb-DO3A-PEG7-Tz [Pb-212]Pb-DO3A-PEG7-Tz | Pb-212 | Therapy | Pretargeting via tetrazine-trans-cyclooctene (TCO) click reaction with TCO-modified antibody | preclinical study | 2 |
| [212Pb]Pb-PSMA-617 PSMA-617 · Pluvicto · [Pb-212]Pb-PSMA-617 | Pb-212 | Therapy | PSMA (prostate-specific membrane antigen) | — | 2 |
| [225Ac]Ac-90-NM600 Ac-225-NM600 | Ac-225 | Therapy | Alkylphosphocholine analog that preferentially accumulates in most tumor types via tumor cell membrane lipid rafts, semiselectively delivering the radioisotope to the tumor microenvironment | — | 2 |
| [225Ac]Ac-DOTA-4AH29 [Ac-225]Ac-DOTA-4AH29 | Ac-225 | Therapy | Fibroblast activation protein (FAP)-targeting single-domain antibody | — | 2 |
| [225Ac]Ac-DOTA-hu3F8 [Ac-225]Ac-DOTA-hu3F8 | Ac-225 | Therapy | GD2 (disialoganglioside) | preclinical | 2 |
| [225Ac]Ac-J591 [Ac-225]Ac-J591 · Ac-225-J591 | Ac-225 | Therapy | Targets prostate-specific membrane antigen (PSMA) via monoclonal antibody J591 | first-in-human phase I dose-escalation trial | 2 |
| [64Cu]Cu-FAPI-2286 [64Cu]Cu-FAPI-2286 · [Cu-64]Cu-FAPI-2286 | Cu-64 | PET | — | — | 2 |
| [67Cu]Cu-SARTATE [Cu-67]Cu-SARTATE · SarTATE | Cu-67 | Therapy | VLA-4 (integrin α4β1) | preclinical study | 2 |
| [68Ga]AAZTA-FAPI-46 [Ga-68]Ga-AAZTA-FAPI-46 | Ga-68 | Therapy | Fibroblast activation protein (FAP) inhibitor targeting FAP-expressing tumor stroma | preclinical study | 2 |
| [68Ga]DOTA-r-a-ABA-iodoCPCR4 | Ga-68 | Therapy | CXCR4 receptor | preclinical study | 2 |
| [68Ga]Ga-ABY-025 [68Ga]Ga-ABY-025 · [68Ga]Ga-ABY-025/PET · [Ga-68]Ga-ABY-025 | Ga-68 | PET | Human epidermal growth factor receptor 2 (HER2) | — | 2 |
| [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 · [68Ga]Ga-DO3A-VS-Cys40-Exendin-4/PET · [Ga-68]Ga-DO3A-VS-Cys40-Exendin-4 | Ga-68 | PET | Glucagon-like peptide-1 receptor (GLP-1R) | — | 2 |
| [68Ga]Ga-DOTA-CP04 [68Ga]Ga-DOTA-CP04 · [Ga-68]Ga-DOTA-CP04 | Ga-68 | PET | Cholecystokinin-2 receptor agonist | — | 2 |
| [68Ga]Ga-DOTA-ECL1i DOTA-ECL1i · Ga-68 DOTA-ECL1i · Ga-68-DOTA-ECL1i | Ga-68 | PET | CCR2 (C-C motif chemokine receptor 2) allosteric antagonist binding | — | 2 |
| [68Ga]Ga-DOTA-Siglec-9 [68Ga]Ga-DOTA-Siglec-9 · [Ga-68]Ga-DOTA-Siglec-9 | Ga-68 | PET | Siglec-9 receptor, binds sialic acid residues on glycoproteins involved in immune cell trafficking and inflammation; related to VAP-1 interaction | — | 2 |
| [68Ga]Ga-DOTA-r-a-ABA-CPCR4 [68Ga]DOTA-r-a-ABA-CPCR4 · [Ga-68]DOTA-r-a-ABA-CPCR4 | Ga-68 | PET | CXCR4 receptor ligand | preclinical study | 2 |
| [68Ga]Ga-oxine [68Ga]Ga-oxine · [68Ga]oxine · [Ga-68]Ga-oxine | Ga-68 | PET | — | — | 2 |
| [68Ga]NOTA-MI-exendin-4 [Ga-68]Ga-NOTA-MI-exendin-4 | Ga-68 | Therapy | GLP-1 receptor (GLP-1R) targeting | Reported once | 2 |
| [89Zr]DFO-F8 [Zr-89]Zr-DFO-F8 | Zr-89 | Therapy | Extra domain A of fibronectin (extracellular matrix protein overexpressed in TNBC stroma) | Reported once | 2 |
| [89Zr]ZrCl4 [89Zr]ZrCl4 | Zr-89 | PET | — | — | 2 |
| [89Zr]hu5A10 [Zr-89]hu5A10 | Zr-89 | Therapy | Targets free PSA (KLK3) | preclinical study | 2 |
| [90Y]Y-90-DOTA-biotin Y-90-DOTA-biotin | Y-90 | Therapy | — | — | 2 |
| [90Y]Y-90-FF-21101 Y-90-FF-21101 | Y-90 | Therapy | Targets P-cadherin | phase I/II clinical trial | 2 |
| [90Y]Y-90-ITGA6B4 Y-90-ITGA6B4 | Y-90 | Therapy | Targets integrin α6β4 (α6β4) overexpressed on tumor cells | — | 2 |
| [90Y]Y-DOTA-DPhe1-Tyr3-octreotide [Y-90]DOTA-DPhe1-Tyr3-octreotide · Y-90-DOTA-D-Phe1-Tyr3-octreotide · [Y-90]DOTA-D-Phe1-Tyr3-octreotide | Y-90 | Therapy | Somatostatin receptor | — | 2 |
| (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide (R)-2-(N-benzyl-4-(2-[18F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide | F-18 | PET | — | — | 1 |
| 10-[11C]methoxy-20(S)-camptothecin 10-[11C]methoxy-20(S)-camptothecin | C-11 | PET | Topoisomerase I | preclinical | 1 |
| [111In]3p-C-NETA-ePSMA-16 [In-111]In-3p-C-NETA-ePSMA-16 | In-111 | Therapy | PSMA (prostate-specific membrane antigen) | Reported once | 1 |
| [111In]AT2S [In-111]In-AT2S | In-111 | Therapy | Binds with high affinity to all five somatostatin receptor subtypes (SST1-5R) | Reported once | 1 |
| [111In]BCY18469 [In-111]In-BCY18469 | In-111 | Therapy | EphA2 (Erythropoietin-producing hepatocellular receptor A2) | preclinical study | 1 |
| [111In]BQ7859 [In-111]In-BQ7859 | In-111 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [111In]DO3A-BODIPY-Tz-TCO-trastuzumab [In-111]In-DO3A-BODIPY-Tz-TCO-trastuzumab | In-111 | Therapy | HER2 (via trastuzumab conjugated through TCO/tetrazine IEDDA reaction) | preclinical study | 1 |
| [111In]DOTA-MSC3 | In-111 | Therapy | Carbonic anhydrase IX (CAIX), a marker of tumor hypoxia | Reported once | 1 |
| [111In]DOTA-TRK-950 [In-111]In-DOTA-TRK-950 | In-111 | Therapy | Targets CAPRIN-1, a cancer-specific cell surface antigen, via the anti-CAPRIN-1 humanized monoclonal antibody TRK-950 | Reported once | 1 |
| [111In]DOTAGA-FAP-2286 [In-111]In-DOTAGA-FAP-2286 | In-111 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [111In]DOTAGA-FAP-2286-ALB [In-111]In-DOTAGA-FAP-2286-ALB | In-111 | Therapy | Fibroblast activation protein (FAP) | preclinical study | 1 |
| [111In]eFAP-6 [In-111]In-eFAP-6 | In-111 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [11C]ABP688 [11C]ABP688 · [C-11]ABP688 · ABP688 | C-11 | PET | — | — | 1 |
| [11C]CP31398 [11C]CP31398 · [C-11]CP31398 | C-11 | PET | — | preclinical study | 1 |
| [11C]CPPC [11C]CPPC · [C-11]CPPC | C-11 | PET | CSF1R (colony-stimulating factor 1 receptor), a biomarker for microglia | — | 1 |
| [11C]ER176 [11C]ER176 · [C-11]ER176 | C-11 | PET | 18 kDa translocator protein (TSPO) | — | 1 |
| [11C]FMZ [11C]flumazenil · [11C]FMZ · [C-11]flumazenil | C-11 | PET | Benzodiazepine receptor ligand | — | 1 |
| [11C]GR103545 [11C]GR103545 · [C-11]GR103545 | C-11 | PET | kappa opioid receptor (KOR) | first-in-human | 1 |
| [11C]KIn83 [11C]KIn83 · [C-11]KIn83 | C-11 | PET | α7 nicotinic acetylcholine receptor (α7-nAChR) radioligand | — | 1 |
| [11C]MTP38 [11C]MTP38 · [C-11]MTP38 | C-11 | PET | Phosphodiesterase 7 (PDE7) | first-in-human | 1 |
| [11C]Me-NB1 [11C]Me-NB1 · [C-11]Me-NB1 | C-11 | PET | GluN2B subunit of the NMDA receptor | first-in-human | 1 |
| [11C]PD153035 C-11 PD153035 · C-11-PD153035 · PD153035 | C-11 | PET | Epidermal growth factor receptor (EGFR) tyrosine kinase domain | investigational (evaluated in patients, pilot clinical studies) | 1 |
| [11C]PK68 [11C]PK68 · [C-11]PK68 | C-11 | PET | Receptor-interacting protein 1 kinase (RIPK1) | — | 1 |
| [11C]PS13 [11C]PS13 · [C-11]PS13 | C-11 | PET | Cyclooxygenase-1 (COX-1) | first-in-human | 1 |
| [11C]RSR-056 [11C]RSR-056 · [C-11]RSR-056 | C-11 | PET | Cannabinoid type 2 receptor (CB2R) | preclinical | 1 |
| [11C]SSI-4 [11C]SSI-4 · [C-11]SSI-4 | C-11 | PET | Stearoyl CoA desaturase 1 (SCD1) | preclinical | 1 |
| [11C]TGN-020 [11C]TGN-020 · [C-11]TGN-020 | C-11 | PET | Aquaporin-4 (AQP4) | — | 1 |
| [11C]YM155 [11C]YM155 · [C-11]YM155 | C-11 | PET | Survivin | — | 1 |
| [11C]carfentanil [11C]carfentanil · [C-11]carfentanil · carfentanil | C-11 | PET | — | — | 1 |
| [11C]phosgene [11C]phosgene · [C-11]phosgene | C-11 | PET | — | — | 1 |
| [123I]PARPi-01 [I-123]PARPi-01 | I-123 | Therapy | PARP1 (Poly (ADP-ribose)-Polymerase 1) targeting Auger emitter therapy | preclinical study | 1 |
| [123I]beta-CIT [123I]beta-CIT · [I-123]beta-CIT | I-123 | SPECT | — | — | 1 |
| [124I]PN67 [I-124]PN67 | I-124 | Therapy | γ-secretase (Notch signaling pathway) inhibitor-based probe | Reported once | 1 |
| [125I]I-BO530 | I-125 | Therapy | Dual targeting of gastrin-releasing peptide receptor (GRPR) and prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [125I]I-Ex-4 | I-125 | Therapy | GLP-1 receptor (GLP-1R) agonist | Reported once | 1 |
| [125I]I-Ex-D3 | I-125 | Therapy | GLP-1 receptor (GLP-1R) agonist binding to pancreatic beta cells | Reported once | 1 |
| [125I]NaIO3 | I-125 | Therapy | — | Reported once | 1 |
| [125I]PARPi-01 | I-125 | Therapy | PARP1 (Poly ADP-ribose Polymerase 1) | preclinical study | 1 |
| [131I]GV-620 | I-131 | Therapy | Prostate-specific membrane antigen (PSMA) inhibitor | Reported once | 1 |
| [131I]I-131-PD-L1 I-131-PD-L1 | I-131 | Therapy | — | — | 1 |
| [131I]I-131-SFMS I-131-SFMS · I-131-SFMs | I-131 | Therapy | Radioembolic agent for transhepatic artery embolization delivering local radiation via iodinated silk fibroin microspheres | — | 1 |
| [131I]I-131-VAT I-131-VAT | I-131 | Therapy | — | — | 1 |
| [131I]I-BNF03 [I-131]I-BNF03 | I-131 | Therapy | Binding to estrogen receptor alpha (ERα) | Reported once | 1 |
| [131I]I-ERIC1 [I-131]I-ERIC1 | I-131 | Therapy | Neural cell adhesion molecule (NCAM) | preclinical study | 1 |
| [131I]I-MIBG [I-131]I-MIBG | I-131 | Therapy | — | — | 1 |
| [131I]I-T-ZHP1 [I-131]I-T-ZHP1 | I-131 | Therapy | HER2, via PNA-mediated pretargeting of trastuzumab | Reported once | 1 |
| [131I]I-Tyr-d-peptide-PEG11-Tz [I-131]I-Tyr-d-peptide-PEG11-Tz | I-131 | Therapy | Click-to-chelate pretargeting via IEDDA reaction between tetrazine probe and TCO-Pertuzumab bound to HER2 | Reported once | 1 |
| [131I]I-WS03 [I-131]I-WS03 | I-131 | Therapy | Estrogen receptor alpha (ERα) binding | Reported once | 1 |
| [131I]KN046 [I-131]KN046 | I-131 | Therapy | PD-L1 and CTLA-4 dual targeting | Reported once | 1 |
| [131I]MAAN [I-131]MAAN | I-131 | Therapy | — | — | 1 |
| [131I]MEGMIB-5F7GGC [I-131]MEGMIB-5F7GGC | I-131 | Therapy | HER2 (human epidermal growth factor receptor 2) | Reported once | 1 |
| [131I]PN67 [I-131]PN67 | I-131 | Therapy | γ-secretase (Notch pathway regulator) | Reported once | 1 |
| [131I]PSMA-769 [I-131]PSMA-769 | I-131 | Therapy | Prostate-specific membrane antigen (PSMA) inhibitor | Reported once | 1 |
| [131I]PSMA-769-d-tyrosine [I-131]PSMA-769-d-tyrosine | I-131 | Therapy | Prostate-specific membrane antigen (PSMA) inhibitor | Reported once | 1 |
| [131I]iodocarvedilol [I-131]iodocarvedilol | I-131 | Therapy | — | — | 1 |
| [161Tb]Tb-3p-C-NETA [161Tb]Tb-3p-C-NETA · [Tb-161]Tb-3p-C-NETA | Tb-161 | Therapy | Somatostatin receptor targeting via TATE (octreotate) peptide | — | 1 |
| [161Tb]Tb-BL02 [Tb-161]Tb-BL02 | Tb-161 | Therapy | CXCR4 (chemokine receptor 4) antagonist-based targeting | preclinical study | 1 |
| [161Tb]Tb-BPAMD [Tb-161]Tb-BPAMD | Tb-161 | Therapy | Hydroxyapatite binding at sites of bone remodeling (bone-seeking bisphosphonate) | — | 1 |
| [161Tb]Tb-DOTA-TOC DOTATOC · DOTA-TOC | Tb-161 | Therapy | Somatostatin receptor (SSTR) agonist | preclinical study | 1 |
| [161Tb]Tb-PSMA-617 PSMA-617 · Pluvicto | Tb-161 | Therapy | Prostate-specific membrane antigen (PSMA) | investigational | 1 |
| [161Tb]Tb-PSMA-I&T PSMA I&T · PSMA-I&T · [Tb-161]Tb-PSMA-I&T | Tb-161 | Therapy | — | — | 1 |
| [161Tb]Tb-cAC10 [Tb-161]Tb-cAC10 | Tb-161 | Therapy | CD30, a receptor overexpressed in lymphomas, targeted via anti-CD30 antibody cAC10 | Reported once | 1 |
| [161Tb]Tb-pepa-pic2-C-Hex-KuE [Tb-161]Tb-pepa-pic2-C-Hex-KuE | Tb-161 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [177Lu]Lu-177-AAZTA5-PSMA-617 Lu-177-AAZTA5-PSMA-617 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) binding via urea-based PSMA-617 pharmacophore | Reported once | 1 |
| [177Lu]Lu-177-OPS201 Lu-177-OPS201 | Lu-177 | Therapy | — | — | 1 |
| [177Lu]Lu-177-OncoFAP-23 Lu-177-OncoFAP-23 | Lu-177 | Therapy | — | — | 1 |
| [177Lu]Lu-3p-C-NETA-ePSMA-16 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) targeting | Reported once | 1 |
| [177Lu]Lu-6S-RedFol-1 [Lu-177]Lu-6S-RedFol-1 | Lu-177 | Therapy | Folate receptor (FR)-targeting | Reported once | 1 |
| [177Lu]Lu-BCY18469 [Lu-177]Lu-BCY18469 | Lu-177 | Therapy | EphA2 (erythropoietin-producing hepatocellular receptor A2) | preclinical study | 1 |
| [177Lu]Lu-BL02 [Lu-177]Lu-BL02 | Lu-177 | Therapy | CXCR4 antagonist targeting CXCR4-expressing tumor cells | preclinical study | 1 |
| [177Lu]Lu-BL34 [Lu-177]Lu-BL34 | Lu-177 | Therapy | C-X-C chemokine receptor 4 (CXCR4) | preclinical study | 1 |
| [177Lu]Lu-CE-21 [Lu-177]Lu-CE-21 | Lu-177 | Therapy | Targets carcinoembryonic antigen (CEA) | first-in-human | 1 |
| [177Lu]Lu-CHX-A''-DTPA-F8 [Lu-177]Lu-CHX-A''-DTPA-F8 | Lu-177 | Therapy | Targets the extra domain A (EDA) of fibronectin, an extracellular matrix protein highly abundant in TNBC stroma | Reported once | 1 |
| [177Lu]Lu-Comb-2 | Lu-177 | Therapy | Targets membrane-bound heat shock protein 70 (mHsp70), overexpressed in glioblastoma, via the TPP sequence | Reported once | 1 |
| [177Lu]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 [Lu-177]Lu-DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 · Lu-177-DOTA-(d-Glu)6-Ala-Tyr-Gly-Trp-Nle-Asp-PheNH2 · Lu-177-DOTA-(dGlu)6-Ala-Tyr-Gly-Trp-Nle-Asp-Phe-NH2 | Lu-177 | Therapy | CCKBR (cholecystokinin B receptor)-targeting radiolabeled minigastrin analogue | — | 1 |
| [177Lu]Lu-DOTA-11E10C11 [Lu-177]Lu-DOTA-11E10C11 | Lu-177 | Therapy | CDH3 (P-cadherin)-targeting monoclonal antibody 11E10C11 | Reported once | 1 |
| [177Lu]Lu-DOTA-2P(FAPI)2 [Lu-177]Lu-DOTA-2P(FAPI)2 · Lu-177-DOTA-2P(FAPI)2 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | preclinical | 1 |
| [177Lu]Lu-DOTA-ABDB6 [Lu-177]Lu-DOTA-ABDB6 | Lu-177 | Therapy | CD70 | Reported once | 1 |
| [177Lu]Lu-DOTA-ABDC2 [Lu-177]Lu-DOTA-ABDC2 | Lu-177 | Therapy | CD47 | Reported once | 1 |
| [177Lu]Lu-DOTA-AE105 [Lu-177]Lu-DOTA-AE105 | Lu-177 | Therapy | Urokinase-type plasminogen activator receptor (uPAR) | Reported once | 1 |
| [177Lu]Lu-DOTA-Affiline-22 [Lu-177]Lu-DOTA-Affiline-22 | Lu-177 | Therapy | — | Reported once | 1 |
| [177Lu]Lu-DOTA-EB-TATE [Lu-177]Lu-DOTA-EB-TATE · Lu-177-DOTA-EB-TATE | Lu-177 | Therapy | Somatostatin receptor binding, with Evans blue moiety for albumin binding to prolong blood residence time | — | 1 |
| [177Lu]Lu-DOTA-FD1 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [177Lu]Lu-DOTA-FD2 [Lu-177]Lu-DOTA-FD2 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [177Lu]Lu-DOTA-FD3 [Lu-177]Lu-DOTA-FD3 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [177Lu]Lu-DOTA-GA13 [Lu-177]Lu-DOTA-GA13 | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK2R) | Reported once | 1 |
| [177Lu]Lu-DOTA-GA4 [Lu-177]Lu-DOTA-GA4 | Lu-177 | Therapy | Cholecystokinin-2 receptor (CCK2R) targeting | preclinical study | 1 |
| [177Lu]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 [Lu-177]Lu-DOTA-His-His-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 | Lu-177 | Therapy | — | Reported once | 1 |
| [177Lu]Lu-DOTA-KiSS-34 [Lu-177]Lu-DOTA-KiSS-34 | Lu-177 | Therapy | KISS1R (kisspeptin receptor) | preclinical study | 1 |
| [177Lu]Lu-DOTA-MI-exendin-4 [Lu-177]Lu-DOTA-MI-exendin-4 | Lu-177 | Therapy | Targets the glucagon-like peptide-1 receptor (GLP-1R) | Reported once | 1 |
| [177Lu]Lu-DOTA-NI-FAPI-04 [Lu-177]Lu-DOTA-NI-FAPI-04 | Lu-177 | Therapy | Fibroblast activation protein (FAP), with additional hypoxia-sensitive nitroimidazole moiety | preclinical | 1 |
| [177Lu]Lu-DOTA-PEG7-tetrazine [Lu-177]Lu-DOTA-PEG7-tetrazine | Lu-177 | Therapy | Click-chemistry pretargeting agent (tetrazine) reacting with TCO-modified FAP-targeted single-domain antibody | preclinical study | 1 |
| [177Lu]Lu-DOTA-POL3026 [Lu-177]Lu-DOTA-POL3026 | Lu-177 | Therapy | CXCR4 (C-X-C chemokine receptor 4) | Reported once | 1 |
| [177Lu]Lu-DOTA-ST8950 [Lu-177]Lu-DOTA-ST8950 | Lu-177 | Therapy | Somatostatin receptor subtypes 2 and 5 (SST2/SST5) | Reported once | 1 |
| [177Lu]Lu-DOTA-TRK-950 [Lu-177]Lu-DOTA-TRK-950 | Lu-177 | Therapy | Targets CAPRIN-1, a cancer-specific cell surface antigen | Reported once | 1 |
| [177Lu]Lu-DOTA-exendin-4 [Lu-177]Lu-DOTA-exendin-4 | Lu-177 | Therapy | GLP-1 receptor (GLP-1R) | — | 1 |
| [177Lu]Lu-DOTA-hG250 [Lu-177]Lu-DOTA-hG250 | Lu-177 | Therapy | Carbonic anhydrase IX (CAIX) | Reported once | 1 |
| [177Lu]Lu-DOTA-iPD-L1 [Lu-177]Lu-DOTA-iPD-L1 | Lu-177 | Therapy | Targets programmed cell death ligand-1 (PD-L1), overexpressed in certain tumors, which inhibits immune response | Reported once | 1 |
| [177Lu]Lu-DOTA-rhCCK-18 [177Lu]Lu-DOTA-rhCCK-18 · [Lu-177]Lu-DOTA-rhCCK-18 | Lu-177 | Therapy | CCK-2 receptor (CCK-2R) targeting | — | 1 |
| [177Lu]Lu-DTPA-NY003 [Lu-177]Lu-DTPA-NY003 | Lu-177 | Therapy | Targets Trophoblast cell-surface antigen-2 (TROP-2), a transmembrane glycoprotein overexpressed in TNBC | preclinical study | 1 |
| [177Lu]Lu-DTPA-PODSAJICAP-5B1 [Lu-177]Lu-DTPA-PODSAJICAP-5B1 | Lu-177 | Therapy | CA19-9 antigen targeting via antibody 5B1 | Reported once | 1 |
| [177Lu]Lu-EB-PSMA-617 [Lu-177]Lu-EB-PSMA-617 · Lu-177-EB-PSMA-617 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) | pilot study | 1 |
| [177Lu]Lu-EB-TATE [Lu-177]Lu-EB-TATE · Lu-177-EB-TATE | Lu-177 | Therapy | SSTR2 agonist targeting somatostatin receptor 2, with albumin-binding Evans blue moiety for prolonged retention | — | 1 |
| [177Lu]Lu-HTK03149 [Lu-177]Lu-HTK03149 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) binding via Lys-urea-Glu pharmacophore | Reported once | 1 |
| [177Lu]Lu-HTK03170 [Lu-177]Lu-HTK03170 | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [177Lu]Lu-LNC1010 [Lu-177]Lu-LNC1010 · Lu-177-LNC1010 | Lu-177 | Therapy | SSTR2 agonist (somatostatin receptor subtype 2) | first-in-human | 1 |
| [177Lu]Lu-LNC1011 [Lu-177]Lu-LNC1011 | Lu-177 | Therapy | — | — | 1 |
| [177Lu]Lu-LW01110 [Lu-177]Lu-LW01110 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) agonist | Reported once | 1 |
| [177Lu]Lu-LW01142 [Lu-177]Lu-LW01142 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) agonist | Reported once | 1 |
| [177Lu]Lu-LW02060 [Lu-177]Lu-LW02060 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) | Reported once | 1 |
| [177Lu]Lu-LW02080 [Lu-177]Lu-LW02080 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | preclinical study | 1 |
| [177Lu]Lu-LuCl3 [Lu-177]LuCl3 | Lu-177 | Therapy | — | — | 1 |
| [177Lu]Lu-NeoBOMB1 [Lu-177]Lu-NeoBOMB1 · NeoBOMB1 · Lu-177-NeoBOMB1 | Lu-177 | Therapy | Gastrin-releasing peptide receptor (GRPR) | — | 1 |
| [177Lu]Lu-OxFol-1 [Lu-177]Lu-OxFol-1 | Lu-177 | Therapy | Folate receptor (FR) targeting | Reported once | 1 |
| [177Lu]Lu-PEG-(DOTA)1 [Lu-177]PEG-(DOTA)1 | Lu-177 | Therapy | — | Reported once | 1 |
| [177Lu]Lu-PEG-(DOTA)1(ACUPA)3 [Lu-177]PEG-(DOTA)1(ACUPA)3 | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) targeting via ACUPA ligand | Reported once | 1 |
| [177Lu]Lu-PEG-Nb159 [Lu-177]Lu-PEG-Nb159 | Lu-177 | Therapy | Targets fibroblast activation protein (FAP) via a nanobody (Nb159) | preclinical study | 1 |
| [177Lu]Lu-PSMA-1-DOTA [Lu-177]Lu-PSMA-1-DOTA | Lu-177 | Therapy | PSMA (prostate-specific membrane antigen) targeting ligand | compassionate use | 1 |
| [177Lu]Lu-PSMA-10 [177Lu]Lu-PSMA-10 · [Lu-177]Lu-PSMA-10 | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA)-targeted urea-based inhibitor | — | 1 |
| [177Lu]Lu-Rituximab [Lu-177]Lu-Rituximab · Lu-177-Rituximab | Lu-177 | Therapy | — | — | 1 |
| [177Lu]Lu-SibuDAB [Lu-177]Lu-SibuDAB | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | — | 1 |
| [177Lu]Lu-cAC10 [Lu-177]Lu-cAC10 | Lu-177 | Therapy | CD30 receptor, overexpressed in lymphomas | Reported once | 1 |
| [177Lu]Lu-eFAP-6 [Lu-177]Lu-eFAP-6 | Lu-177 | Therapy | Fibroblast activation protein (FAP) | preclinical study | 1 |
| [177Lu]Lu-satoreotide [Lu-177]Lu-satoreotide · [Lu-177]Lu-Satoreotide · Lu-177-Satoreotide | Lu-177 | Therapy | Somatostatin receptor 2 (SST2) antagonist | — | 1 |
| [177Lu]Lu-uPAR-02 [Lu-177]Lu-uPAR-02 | Lu-177 | Therapy | Targets the urokinase-type plasminogen activator receptor (uPAR) | Reported once | 1 |
| [177Lu]Lu-vMET1-Fc [Lu-177]Lu-vMET1-Fc | Lu-177 | Therapy | Targets MET receptor tyrosine kinase | Reported once | 1 |
| [188Re]Re-188-HEDP Re-188-HEDP · Re-188-Sn-HEDP | Re-188 | Therapy | — | — | 1 |
| [188Re]Re-188-HYNIC-BBN Re-188-HYNIC-BBN · Re-188-HYNICBBN | Re-188 | Therapy | Gastrin-releasing peptide receptor (GRPR) | — | 1 |
| [18F](E)-PSS232 [18F](E)-PSS232 | F-18 | PET | metabotropic glutamate receptor subtype 5 (mGlu5) | — | 1 |
| [18F]ADPM06 [18F]ADPM06 · [F-18]ADPM06 | F-18 | PET | — | — | 1 |
| [18F]AG-120 [18F]AG-120 · [F-18]AG-120 | F-18 | PET | Mutant isocitrate dehydrogenase 1 (IDH1R132H) | preclinical study | 1 |
| [18F]AQ28A [18F]AQ28A · [F-18]AQ28A | F-18 | PET | Phosphodiesterase 10A (PDE10A) | preclinical | 1 |
| [18F]AlF [18F]AlF · [18F]AlF2+ · [F-18]AlF | F-18 | PET | Integrin αvβ3 | — | 1 |
| [18F]AlF-3p-C-NETA-ePSMA-16 [F-18]AlF-3p-C-NETA-ePSMA-16 | F-18 | Therapy | PSMA-targeting | Reported once | 1 |
| [18F]AlF-H3RESCA-FAPI [F-18]AlF-H3RESCA-FAPI | F-18 | Therapy | Fibroblast activation protein (FAP) | preclinical study | 1 |
| [18F]AlF-NOTA-DV1-k-(DV3) [F-18]AlF-NOTA-DV1-k-(DV3) | F-18 | Therapy | CXCR4 (C-X-C chemokine receptor 4) | Reported once | 1 |
| [18F]AlF-NOTA-T140 [F-18]AlF-NOTA-T140 | F-18 | Therapy | CXCR4 (chemokine receptor 4) | Reported once | 1 |
| [18F]AlF-NOTA-iPD-L1 [F-18]AlF-NOTA-iPD-L1 · [F-18]AlF-NOTA-iPD-L1/ | F-18 | Therapy | PD-L1 (programmed cell death ligand-1) | Reported once | 1 |
| [18F]AlF-NOTA-ubiquicidin 29-41 [18F]AlF-NOTA-ubiquicidin 29-41 | F-18 | PET | Binds bacterial cell membranes | — | 1 |
| [18F]AlF-RESCA-5F7 [F-18]AlF-RESCA-5F7 | F-18 | Therapy | Targets HER2 (human epidermal growth factor receptor 2) expression | Reported once | 1 |
| [18F]ApaScan [18F]ApaScan | F-18 | PET | CYP11B2 (aldosterone synthase) | preclinical (preparing for first-in-human studies) | 1 |
| [18F]BIBD-239 [18F]BIBD-239 · [F-18]BIBD-239 | F-18 | PET | Translocator protein (TSPO) | first-in-human | 1 |
| [18F]BPAM121 [18F]BPAM121 · [F-18]BPAM121 · BPAM121 | F-18 | PET | AMPA receptor (ionotropic glutamate receptor) positive allosteric modulator | Research | 1 |
| [18F]BTK-1 [18F]BTK-1 · [F-18]BTK-1 | F-18 | PET | Bruton's tyrosine kinase (BTK) | preclinical | 1 |
| [18F]CbR [18F]CbR | F-18 | PET | — | — | 1 |
| [18F]DPA-C5yne [18F]DPA-C5yne · [F-18]DPA-C5yne | F-18 | PET | translocator protein 18 kDa (TSPO) | preclinical | 1 |
| [18F]EKZ-001 [18F]EKZ-001 · [F-18]EKZ-001 | F-18 | PET | HDAC6 (histone deacetylase 6) radioligand | preclinical (supporting first-in-human translation) | 1 |
| [18F]F-A-85380 [18F]F-A-85380 · [F-18]F-A-85380 | F-18 | PET | α4β2 nicotinic acetylcholine receptors (nAChRs) | — | 1 |
| [18F]FB-2BD42 [18F]FB-2BD42 · [F-18]FB-2BD42 | F-18 | PET | Targets folate receptor-alpha (FR-α), which has elevated expression in epithelial cancers such as ovarian, brain and lung cancers | — | 1 |
| [18F]FB-A20FMDV2 [18F]FB-A20FMDV2 · [F-18]FB-A20FMDV2 | F-18 | PET | Binds selectively to integrin αvβ6 | preclinical study | 1 |
| [18F]FB-IL2 [18F]FB-IL-2 · [18F]FB-IL2 · [F-18]FB-IL-2 | F-18 | PET | Targets interleukin-2 (IL2) receptors on activated T-cells | — | 1 |
| [18F]FB-S100s [18F]FB-S100s · [F-18]FB-S100s | F-18 | PET | Pattern recognition receptors, e.g., Toll-like receptors (TLRs), the receptor for advanced glycation end products (RAGE), or scavenger receptors (SR) | preclinical | 1 |
| [18F]FBAM [18F]FBAM · [F-18]FBAM | F-18 | PET | Phosphatidylserine (PS) | preclinical | 1 |
| [18F]FBEM-Cys-H4 [18F]FBEM-Cys-H4 · [F-18]FBEM-Cys-H4 | F-18 | PET | — | — | 1 |
| [18F]FCPPC [18F]FCPPC | F-18 | PET | Colony-stimulating factor 1 receptor (CSF1R), expressed on microglia | — | 1 |
| [18F]FDDNP [18F]FDDNP · [F-18]FDDNP · FDDNP | F-18 | PET | beta-amyloid plaques and tau neurofibrillary tangle aggregates | — | 1 |
| [18F]FDR [18F]FDR | F-18 | PET | — | — | 1 |
| [18F]FG-CP31398 [18F]FG-CP31398 · [F-18]FG-CP31398 | F-18 | PET | — | — | 1 |
| [18F]FMN3PA [18F]FMN3PA · [F-18]FMN3PA | F-18 | PET | — | — | 1 |
| [18F]FMN3PU [18F]FMN3PU · [F-18]FMN3PU | F-18 | PET | leucine-rich repeat kinase 2 (LRRK2) | preclinical | 1 |
| [18F]FPG-IL4 [18F]FPG-IL4 · [F-18]FPG-IL4 | F-18 | PET | — | — | 1 |
| [18F]FTC-146 [18F]FTC-146 · [F-18]FTC-146 | F-18 | PET | sigma-1 receptor (S1R) | first-in-human | 1 |
| [18F]GE-226 [18F]GE-226 · [F-18]GE-226 · GE-226 | F-18 | PET | HER2 (human epidermal growth factor receptor 2); HER2-binding Affibody molecule ZHER2:2891 | Research | 1 |
| [18F]HX4 [18F]HX4 · [F-18]HX4 | F-18 | PET | — | — | 1 |
| [18F]JMV5763 [18F]JMV5763 · [F-18]JMV5763 | F-18 | PET | — | — | 1 |
| [18F]JNJ-46356479 [18F]JNJ-46356479 · [F-18]JNJ-46356479 | F-18 | PET | — | — | 1 |
| [18F]K10-008 [18F]K10-008 · [F-18]K10-008 | F-18 | PET | Aβ (beta-amyloid) deposits | — | 1 |
| [18F]MEL050 [18F]MEL050 · [F-18]MEL050 | F-18 | PET | Melanin | phase I | 1 |
| [18F]MIPS15692 [18F]MIPS15692 · [F-18]MIPS15692 | F-18 | PET | MER tyrosine kinase (MERTK) | preclinical | 1 |
| [18F]NOTA-ABY-030 [18F]NOTA-ABY-030 · [F-18]NOTA-ABY-030 | F-18 | PET | Epidermal Growth Factor Receptor (EGFR) | — | 1 |
| [18F]NS10743 [18F]NS10743 · [F-18]NS10743 | F-18 | PET | alpha7 nicotinic acetylcholine receptor (α7 nAChR) | preclinical | 1 |
| [18F]NaBF4 [F-18]NaBF4 | F-18 | Therapy | Uptake via sodium-iodide symporter (NIS) expressed on thyroid cell surface | Reported once | 1 |
| [18F]OP-801 [18F]OP-801 · [F-18]OP-801 | F-18 | PET | Selectively taken up by reactive microglia and macrophages | phase 1/2 clinical trial (first-in-human) | 1 |
| [18F]PBR06 [18F]PBR06 · [F-18]PBR06 · F-18 PBR06 | F-18 | PET | 18-kDa translocator protein (TSPO), a marker of microglial/astrocytic activation | — | 1 |
| [18F]PM-PBB3 [18F]APN-1607 · [18F]PM-PBB3 · [F-18]APN-1607 | F-18 | PET | Tau pathology | — | 1 |
| [18F]SMBT-1 [18F]SMBT-1 · [F-18]SMBT-1 · F-18 SMBT-1 | F-18 | PET | Reactive astrogliosis / astrocyte imaging marker | — | 1 |
| [18F]THK-5117 [18F]THK-5117 · [18F]THK5117 · [F-18]THK-5117 | F-18 | PET | Tau neurofibrillary tangles | — | 1 |
| [18F]TTCO-IL2 [18F]TTCO-IL2 · [F-18]TTCO-IL2 · trans-cyclooctene labelled interleukin-2 | F-18 | PET | Interleukin-2 receptor (subunits CD25/CD122/CD132) on activated T-cells; TCO-modified interleukin-2 (IL2) radioconjugate | Research | 1 |
| [18F]UCB-H [18F]UCB-H · [F-18]UCB-H | F-18 | PET | — | — | 1 |
| [18F]VAT [18F]VAT | F-18 | PET | Vesicular acetylcholine transporter (VAChT), presynaptic cholinergic biomarker | — | 1 |
| [18F]fiau [18F]FIAU · [F-18]FIAU · FIAU | F-18 | PET | Thymidine kinase (bacterial TK / HSV1-tk reporter gene) | investigational | 1 |
| [18F]fluoroazomycin-2'-deoxyribofuranoside [18F]fluoroazomycin-2'-deoxyribofuranoside | F-18 | PET | Reductive trapping in hypoxic cells (2-nitroimidazole hypoxia marker, mimicking nucleoside transport) | preclinical | 1 |
| [18F]fluorocellobiose [18F]Fluorocellobiose · [F-18]Fluorocellobiose | F-18 | PET | β-glucosidase-mediated hydrolysis of fluorocellobiose to [18F]FDG by cellulolytic fungal metabolism | preclinical | 1 |
| [18F]fluorosulfate [18F]fluorosulfate · [F-18]fluorosulfate | F-18 | PET | human sodium-iodide symporter (hNIS) | preclinical | 1 |
| [18F]mBPET-1 [18F]mBPET-1 · [F-18]mBPET-1 | F-18 | PET | mTOR kinase (mTORC1) inhibitor-based probe | — | 1 |
| [18F]mG4P027 [18F]mG4P027 · [F-18]mG4P027 | F-18 | PET | metabotropic glutamate receptor 4 (mGluR4) | — | 1 |
| [203Pb]eSOMA-01 | Pb-203 | Therapy | Somatostatin receptor subtype 2 (SSTR2) | Reported once | 1 |
| [203Pb]eSOMA-02 | Pb-203 | Therapy | Somatostatin receptor subtype 2 (SSTR2) | Reported once | 1 |
| [203Pb]eSOMA-03 | Pb-203 | Therapy | Somatostatin receptor type 2 (SSTR2) binding via octreotate-based ligand | Reported once | 1 |
| [211At]At-211-APBA-FAPI At-211-APBA-FAPI | At-211 | Therapy | — | — | 1 |
| [211At]At-L3-Lu [At-211]L3-Lu | At-211 | Therapy | PSMA (prostate-specific membrane antigen) | Reported once | 1 |
| [211At]At-NaAtO3 [At-211]NaAtO3 | At-211 | Therapy | — | Reported once | 1 |
| [211At]At-astato-benzylguanidine [At-211]astato-benzylguanidine · [At-211]astatobenzylguanidine · [At-211]At-astatobenzylguanidine | At-211 | Therapy | — | — | 1 |
| [211At]At-astatobenzamide-N-3-hydroxypropylidene-3 [At-211]astatobenzamide-N-3-hydroxypropylidene-3 · [At-211]astato-benzamide-N-3-hydroxypropylidene-3 | At-211 | Therapy | bone mineral (hydroxyapatite)-binding bisphosphonate | preclinical | 1 |
| [211At]At-astatophenethylsuccinamate [At-211]astatophenethylsuccinamate | At-211 | Therapy | IL-2 receptor alpha-chain (IL-2Ralpha) via humanized anti-Tac antibody | preclinical | 1 |
| [212Pb]Pb-DOTAM-GRPR1 [Pb-212]Pb-DOTAM-GRPR1 | Pb-212 | Therapy | Gastrin-releasing peptide receptor (GRPR)-targeting peptide | preclinical study | 1 |
| [212Pb]Pb-FAPI-46 FAPI-46 · [Pb-212]Pb-FAPI-46 | Pb-212 | Therapy | Targets fibroblast activation protein (FAP) expressed by cancer-associated fibroblasts in tumor stroma | — | 1 |
| [212Pb]Pb-eSOMA-02 | Pb-212 | Therapy | SSTR2 (somatostatin receptor subtype 2) | Reported once | 1 |
| [213Bi]Bi-3p-C-NETA-ePSMA-16 | Bi-213 | Therapy | PSMA (prostate-specific membrane antigen) targeting | Reported once | 1 |
| [213Bi]Bi-PSMA-617 PSMA-617 · Pluvicto | Bi-213 | Therapy | Prostate-specific membrane antigen (PSMA) | — | 1 |
| [213Bi]Bi-anti-CD20 [Bi-213]anti-CD20 | Bi-213 | Therapy | CD20 antigen on non-Hodgkin lymphoma cells | Reported once | 1 |
| [225Ac]Ac(MacropaSq-hG250) [Ac-225]Ac(MacropaSq-hG250) | Ac-225 | Therapy | Binds carbonic anhydrase IX (CAIX), overexpressed on clear cell renal cell carcinoma cells | preclinical study | 1 |
| [225Ac]Ac-225-DOTA-J591 Ac-225-DOTA-J591 | Ac-225 | Therapy | — | — | 1 |
| [225Ac]Ac-3p-C-DEPA-NO2 [Ac-225]Ac-3p-C-DEPA-NO2 | Ac-225 | Therapy | — | preclinical study | 1 |
| [225Ac]Ac-3p-C-DEPA-TFP-PEG4-trastuzumab [Ac-225]Ac-3p-C-DEPA-TFP-PEG4-trastuzumab | Ac-225 | Therapy | — | preclinical study | 1 |
| [225Ac]Ac-3p-C-DEPA-trastuzumab [Ac-225]Ac-3p-C-DEPA-trastuzumab | Ac-225 | Therapy | — | preclinical study | 1 |
| [225Ac]Ac-DOTA-2Rs15d [Ac-225]Ac-DOTA-2Rs15d | Ac-225 | Therapy | HER2 (human epidermal growth factor receptor type 2) | preclinical study | 1 |
| [225Ac]Ac-DOTA-CCK-66 [Ac-225]Ac-DOTA-CCK-66 | Ac-225 | Therapy | Cholecystokinin-2 (CCK2)/gastrin receptor targeting minigastrin analog | preclinical study | 1 |
| [225Ac]Ac-DOTA-LM3 [Ac-225]Ac-DOTA-LM3 | Ac-225 | Therapy | Somatostatin receptor subtype 2 (SSTR2) antagonist | first-in-human | 1 |
| [225Ac]Ac-DOTA-MSC3 [Ac-225]Ac-DOTA-MSC3 | Ac-225 | Therapy | Carbonic anhydrase IX (CAIX), expressed on hypoxic tumor cells | preclinical study | 1 |
| [225Ac]Ac-DOTA-PKU525 [Ac-225]Ac-DOTA-PKU525 | Ac-225 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [225Ac]Ac-DOTA-TA99 [Ac-225]Ac-DOTA-TA99 | Ac-225 | Therapy | — | Reported once | 1 |
| [225Ac]Ac-DOTA-anti-CD33 [Ac-225]DOTA-anti-CD33 | Ac-225 | Therapy | CD33 | clinical stage | 1 |
| [225Ac]Ac-DOTAGA-FAP-2286-ALB [Ac-225]Ac-DOTAGA-FAP-2286-ALB | Ac-225 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [225Ac]Ac-DOTAZOL [Ac-225]Ac-DOTAZOL · DOTAZOL | Ac-225 | Therapy | Bone mineral (hydroxyapatite) targeting via bisphosphonate moiety | preclinical | 1 |
| [225Ac]Ac-FAPI-04 FAPI-04 · [Ac-225]Ac-FAPI-04 | Ac-225 | Therapy | Targets fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts | preclinical | 1 |
| [225Ac]Ac-FAPI-46 FAPI-46 | Ac-225 | Therapy | Fibroblast activation protein (FAP) | preclinical study | 1 |
| [225Ac]Ac-Macropa-7065 [Ac-225]Macropa-7065 | Ac-225 | Therapy | Active conformation of integrin-β2 (aITGB2), a tumor-selective epitope on AML cells, targeted by conformation-specific antibody clone 7065 | — | 1 |
| [225Ac]Ac-Macropa-N4MU01 [Ac-225]Ac-Macropa-N4MU01 | Ac-225 | Therapy | Nectin-4, overexpressed in triple-negative breast cancer, targeted by fully human anti-nectin-4 antibody N4MU01 | Reported once | 1 |
| [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1 [Ac-225]Ac-Macropa-pertuzumab-PEG6-DM1 | Ac-225 | Therapy | HER2 (human epidermal growth factor receptor 2) | preclinical study | 1 |
| [225Ac]Ac-Pep-1L [Ac-225]Pep-1L | Ac-225 | Therapy | IL13RA2 (interleukin 13 receptor alpha 2) targeting peptide | Reported once | 1 |
| [225Ac]Ac-hu11B6 [Ac-225]Ac-hu11B6 · [Ac-225]hu11B6 | Ac-225 | Therapy | Targets human kallikrein 2 (hK2), an androgen receptor gene product, delivering alpha-particle emitting Actinium-225 to AR-expressing tumor tissue | — | 1 |
| [225Ac]Ac-hu5A10 [Ac-225]hu5A10 | Ac-225 | Therapy | Targets free PSA (KLK3) | Reported once | 1 |
| [225Ac]Ac-mcp-PEG8-Tz [Ac-225]Ac-mcp-PEG8-Tz | Ac-225 | Therapy | Pretargeting via inverse-electron-demand Diels-Alder click reaction between tetrazine (Tz) on the chelator-radionuclide complex and trans-cyclooctene (TCO) conjugated to anti-MUC16 antibody AR9.6 | Reported once | 1 |
| [225Ac]Ac-mcp-TDI-Y-010 [Ac-225]Ac-mcp-TDI-Y-010 | Ac-225 | Therapy | Anti-delta-like ligand 3 (DLL3) monoclonal antibody targeting DLL3-positive neuroendocrine cancer cells | Reported once | 1 |
| [44Sc]177-AAZTA5-PSMA-617 | Sc-44 | Therapy | PSMA (prostate-specific membrane antigen) | Reported once | 1 |
| [47Sc]Sc-PSMA-617 PSMA-617 · Pluvicto | Sc-47 | Therapy | Prostate-specific membrane antigen (PSMA) | preclinical study | 1 |
| [64Cu]Pep-1L [Cu-64]Pep-1L | Cu-64 | Therapy | IL13RA2 (interleukin 13 receptor alpha 2) targeted peptide | Reported once | 1 |
| [64Cu]SarAr-PEG10-Tz [Cu-64]Cu-SarAr-PEG10-Tz | Cu-64 | Therapy | Tetrazine-trans-cyclooctene inverse electron-demand Diels-Alder (IEDDA) pretargeting ligation with TCO-bearing huA33 anti-A33 antibody | Reported once | 1 |
| [67Cu]Cu-SarAr-PEG10-Tz [Cu-67]Cu-SarAr-PEG10-Tz | Cu-67 | Therapy | Tetrazine-trans-cyclooctene inverse electron-demand Diels-Alder (IEDDA) ligation for pretargeting a TCO-bearing anti-A33 antibody (huA33-TCO) | Reported once | 1 |
| [67Cu]Cu-pertuzumab-PEG6-DM1 [Cu-67]Cu-pertuzumab-PEG6-DM1 | Cu-67 | Therapy | HER2-targeting via pertuzumab (domain II) antibody-drug conjugate | Reported once | 1 |
| [67Ga]Comb-2 | Ga-67 | Therapy | Membrane-bound heat shock protein 70 (mHsp70) targeting via TPP sequence, with BBB penetration via d-PepH3 sequence | Reported once | 1 |
| [68Ga]177-AAZTA5-PSMA-617 | Ga-68 | Therapy | PSMA (prostate-specific membrane antigen) binding | Reported once | 1 |
| [68Ga]BCY18469 [Ga-68]Ga-BCY18469 | Ga-68 | Therapy | EphA2 (erythropoietin-producing hepatocellular receptor A2) | Reported once | 1 |
| [68Ga]BL34 [Ga-68]Ga-BL34 | Ga-68 | Therapy | CXCR4 (C-X-C chemokine receptor 4) antagonist/binder | preclinical study | 1 |
| [68Ga]C803-GIP [Ga-68]Ga-C803-GIP | Ga-68 | Therapy | GIPR (glucose-dependent insulinotropic polypeptide receptor) | Reported once | 1 |
| [68Ga]CE-21 [Ga-68]Ga-CE-21 | Ga-68 | Therapy | Carcinoembryonic antigen (CEA) | first-in-human | 1 |
| [68Ga]DOTA-A1-His [Ga-68]Ga-DOTA-A1-His | Ga-68 | Therapy | Mesothelin-targeting single-domain antibody (sdAb) | preclinical | 1 |
| [68Ga]DOTA-FD1 [Ga-68]Ga-DOTA-FD1 | Ga-68 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [68Ga]DOTA-FD2 | Ga-68 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [68Ga]DOTA-FD3 | Ga-68 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [68Ga]DOTA-KiSS-34 | Ga-68 | Therapy | KISS1R (kisspeptin receptor) | Reported once | 1 |
| [68Ga]DOTA-MGS8 [Ga-68]Ga-DOTA-MGS8 | Ga-68 | Therapy | Cholecystokinin-2 receptor (CCK2R) | preclinical study | 1 |
| [68Ga]Ga-3p-C-NETA [68Ga]Ga-3p-C-NETA · [Ga-68]Ga-3p-C-NETA | Ga-68 | PET | — | preclinical study | 1 |
| [68Ga]Ga-BOT5035 [68Ga]Ga-BOT5035 · [Ga-68]Ga-BOT5035 | Ga-68 | PET | Platelet derived growth factor receptor β (PDGFR-β) | phase I | 1 |
| [68Ga]Ga-D0103 D0103 · Ga-68 D0103 · Ga-68-D0103 | Ga-68 | PET | αvβ6-integrin (ITGB6) targeting | — | 1 |
| [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 [68Ga]Ga-DO3A-Tuna-2 · [68Ga]Ga-DO3A-VS-Cys40-S01-GCG · [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 | Ga-68 | PET | Glucagon receptor (GCGR) binding | — | 1 |
| [68Ga]Ga-DOTA-Z09591 [68Ga]Ga-ATH001 · [68Ga]Ga-DOTA-Z09591 · [Ga-68]Ga-DOTA-Z09591 | Ga-68 | PET | Platelet-derived growth factor receptor beta (PDGFRβ) | phase 0 clinical study | 1 |
| [68Ga]Ga-EMP100 [68Ga]Ga-EMP100 · [Ga-68]Ga-EMP100 | Ga-68 | PET | c-MET (transmembrane receptor) | — | 1 |
| [68Ga]Ga-NOTA-BBN2 [68Ga]Ga-NOTA-BBN2 · [Ga-68]Ga-NOTA-BBN2 | Ga-68 | PET | — | preclinical | 1 |
| [68Ga]Ga-P16-093 [68Ga]Ga-P16-093 · [Ga-68]Ga-P16-093 | Ga-68 | PET | Prostate-specific membrane antigen (PSMA) | Phase 2 clinical trial | 1 |
| [68Ga]HNI01 [Ga-68]Ga-HNI01 | Ga-68 | Therapy | — | Reported once | 1 |
| [68Ga]HTK03149 [Ga-68]Ga-HTK03149 | Ga-68 | Therapy | PSMA (prostate-specific membrane antigen) targeting via Lys-urea-Glu pharmacophore | Reported once | 1 |
| [68Ga]HTK03161 [Ga-68]Ga-HTK03161 | Ga-68 | Therapy | PSMA (prostate-specific membrane antigen) | Reported once | 1 |
| [68Ga]HTK03177 [Ga-68]Ga-HTK03177 | Ga-68 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [68Ga]HTK03187 [Ga-68]Ga-HTK03187 | Ga-68 | Therapy | Binds prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [68Ga]HTK03189B [Ga-68]Ga-HTK03189B | Ga-68 | Therapy | PSMA (prostate-specific membrane antigen) targeting via Lys-urea-based pharmacophore | Reported once | 1 |
| [68Ga]LW02060 [Ga-68]Ga-LW02060 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) agonist | Reported once | 1 |
| [68Ga]LW02080 [Ga-68]Ga-LW02080 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | Reported once | 1 |
| [68Ga]NOTA-A1-His [Ga-68]Ga-NOTA-A1-His | Ga-68 | Therapy | Mesothelin | preclinical study | 1 |
| [68Ga]NOTA-ABDC2 [Ga-68]Ga-NOTA-ABDC2 | Ga-68 | Therapy | CD47-targeting agent | Reported once | 1 |
| [68Ga]NOTA-C2 [Ga-68]Ga-NOTA-C2 | Ga-68 | Therapy | CD47 | Reported once | 1 |
| [68Ga]PEG2-COU [Ga-68]Ga-PEG2-COU | Ga-68 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [68Ga]PEG6-COU [Ga-68]Ga-PEG6-COU | Ga-68 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [68Ga]PKB2 [Ga-68]Ga-PKB2 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) targeting | Reported once | 1 |
| [68Ga]PKB3 [Ga-68]Ga-PKB3 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist/binder | Reported once | 1 |
| [68Ga]PSMA-1-DOTA | Ga-68 | Therapy | PSMA (prostate-specific membrane antigen) | compassionate use | 1 |
| [68Ga]S02-GIP-T4 [Ga-68]S02-GIP-T4 | Ga-68 | Therapy | GIP receptor (GIPR) | Reported once | 1 |
| [68Ga]SB02055 [Ga-68]Ga-SB02055 | Ga-68 | Therapy | Fibroblast activation protein (FAP) | preclinical study | 1 |
| [68Ga]SB04028 [Ga-68]Ga-SB04028 | Ga-68 | Therapy | Fibroblast activation protein (FAP) inhibitor | preclinical study | 1 |
| [68Ga]TATE-46 [Ga-68]Ga-TATE-46 | Ga-68 | Therapy | Dual targeting of SSTR2 and FAP | preclinical study | 1 |
| [68Ga]TacBOMB2 [Ga-68]Ga-TacBOMB2 | Ga-68 | Therapy | GRPR agonist | Reported once | 1 |
| [68Ga]TacBOMB3 [Ga-68]Ga-TacBOMB3 | Ga-68 | Therapy | GRPR agonist | Reported once | 1 |
| [68Ga]TacsBOMB2 [Ga-68]Ga-TacsBOMB2 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | Reported once | 1 |
| [68Ga]TacsBOMB3 [Ga-68]Ga-TacsBOMB3 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | Reported once | 1 |
| [68Ga]TacsBOMB6 [Ga-68]Ga-TacsBOMB6 | Ga-68 | Therapy | Gastrin-releasing peptide receptor (GRPR) antagonist | Reported once | 1 |
| [86Y]pepa-pic2 | Y-86 | Therapy | — | Reported once | 1 |
| [86Y]pepa-pic2-C-Hex-KuE | Y-86 | Therapy | Prostate-specific membrane antigen (PSMA) | Reported once | 1 |
| [89Zr]DFO-11E10C11 [Zr-89]Zr-DFO-11E10C11 | Zr-89 | Therapy | CDH3 (P-cadherin) targeting via anti-CDH3 monoclonal antibody 11E10C11 | Reported once | 1 |
| [89Zr]DFO-NY003/ [Zr-89]Zr-DFO-NY003/ | Zr-89 | Therapy | TROP-2 (trophoblast cell-surface antigen-2) | preclinical study | 1 |
| [89Zr]DFO-Per-F(ab')2 [Zr-89]Zr-DFO-Per-F(ab')2 | Zr-89 | Therapy | HER2-targeting via Pertuzumab-derived F(ab')2 fragment | Reported once | 1 |
| [89Zr]Nb159 [Zr-89]Zr-Nb159 | Zr-89 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [89Zr]PEG-Nb159 | Zr-89 | Therapy | Fibroblast activation protein (FAP) | Reported once | 1 |
| [89Zr]Zr-Df-pertuzumab-800CW Df-pertuzumab-800CW · Zr-89 Df-pertuzumab-800CW · Zr-89-Df-pertuzumab-800CW | Zr-89 | PET | HER2 (human epidermal growth factor receptor 2) | — | 1 |
| [89Zr]Zr-TROP2 [89Zr]TROP2 · [Zr-89]TROP2 | Zr-89 | PET | Trophoblast cell surface antigen 2 (TROP-2) | preclinical | 1 |
| [89Zr]trastuzumab-PEG6-DM1 [Zr-89]Zr-trastuzumab-PEG6-DM1 | Zr-89 | Therapy | HER2 (domain IV targeting antibody-drug conjugate) | Reported once | 1 |
| [89Zr]vMET1-Fc [Zr-89]Zr-vMET1-Fc | Zr-89 | Therapy | Targets MET receptor tyrosine kinase, internalized by MET-positive cells | preclinical study | 1 |
| [90Y]Y-90-DOTATOC/DOTATATE Y-90-DOTATOC/DOTATATE | Y-90 | Therapy | — | — | 1 |
| [90Y]Y-90-DTPA-rituximab Y-90-DTPA-rituximab · Y-90-DTPA-Rituximab | Y-90 | Therapy | CD20 | — | 1 |
| [90Y]Y-90-NM600 Y-90-NM600 | Y-90 | Therapy | — | — | 1 |
| [90Y]Y-FAPI [90Y]FAPI · [Y-90]FAPI · FAPI | Y-90 | Therapy | Fibroblast activation protein (FAP) expressed on cancer-associated fibroblasts (CAFs) | — | 1 |
| [90Y]Y-L4-Lipo/ [Y-90]Y-L4-Lipo/ | Y-90 | Therapy | — | Reported once | 1 |
| [90Y]Y-anti-CD66 [Y-90]Y-Anti-CD66 · [Y-90]anti-CD66 | Y-90 | Therapy | CD66b-specific monoclonal antibody targeting bone marrow myeloid cells | — | 1 |
| [90Y]Y-hu5A10 [Y-90]hu5A10 | Y-90 | Therapy | Targets free PSA (KLK3) | preclinical study | 1 |
| [99mTc]HYNIC-MGS11 [Tc-99m]Tc-HYNIC-MGS11 | Tc-99m | Therapy | Cholecystokinin-2 receptor (CCK2R) targeting | Reported once | 1 |
| [99mTc]HYNIC-MGS5 [Tc-99m]Tc-HYNIC-MGS5 | Tc-99m | Therapy | Cholecystokinin-2 receptor (CCK2R) | Reported once | 1 |
| [99mTc]N4-CCK-100 [Tc-99m]Tc-N4-CCK-100 | Tc-99m | Therapy | Cholecystokinin-2 receptor (CCK-2R) | preclinical study | 1 |
| [99mTc]N4-CCK-104 [Tc-99m]Tc-N4-CCK-104 | Tc-99m | Therapy | Cholecystokinin-2 receptor (CCK-2R) | preclinical study | 1 |
| [99mTc]N4-CCK-66 [Tc-99m]Tc-N4-CCK-66 | Tc-99m | Therapy | Cholecystokinin-2 receptor (CCK-2R) ligand | Reported once | 1 |
| [99mTc]Tc(CO)3-ADAPT6 [Tc-99m]Tc(CO)3-ADAPT6 | Tc-99m | Therapy | HER2 (human epidermal growth factor receptor 2) | Reported once | 1 |
| [99mTc]Tc(CO)3-GRGDHV [Tc-99m]Tc(CO)3-GRGDHV | Tc-99m | Therapy | αvβ3 integrin | Reported once | 1 |
| [99mTc]Tc(CO)3-NOTA-AocNle-CycMSHhex [Tc-99m]Tc(CO)3-NOTA-AocNle-CycMSHhex | Tc-99m | Therapy | MC1R (melanocortin 1 receptor)-specific binding on melanoma cells | Reported once | 1 |
| [99mTc]Tc(CO)3-NOTA-PEG2Nle-CycMSHhex [Tc-99m]Tc(CO)3-NOTA-PEG2Nle-CycMSHhex | Tc-99m | Therapy | Melanocortin 1 receptor (MC1R) specific binding | Reported once | 1 |
| [99mTc]Tc-N4-PSMA-12 [99mTc]Tc-N4-PSMA-12 · [Tc-99m]Tc-N4-PSMA-12 | Tc-99m | SPECT | Prostate-specific membrane antigen (PSMA) inhibitor | preclinical study | 1 |
| [99mTc]Tc-TcO2 [99mTc]TcO2 · [Tc-99m]TcO2 | Tc-99m | SPECT | — | — | 1 |
| 2-[18F]fluoro-myo-inositol 2-[18F]fluoro-myo-inositol | F-18 | PET | Inositol uptake/transport related to membrane lipid metabolism and mitogenic signaling | preclinical | |
| 2-[18F]fluoroethyl tosylate [18F]FETos · [F-18]FETos | F-18 | n/a | n/a | n/a | |
| 2-[211At]astato-α-methyl-L-phenylalanine 2-[211At]AAMP · [211At]AAMP | At-211 | Therapy | L-type amino acid transporter 1 (LAT1), highly expressed in various human cancers; cellular uptake inhibited by an LAT1-selective inhibitor | preclinical | |
| 3-[18F]fluoropropyl tosylate 3-[18F]fluoropropyl tosylate · [18F]fluoro-1-(4-methylphenylsulfonyloxy)propane | F-18 | n/a | n/a | n/a | |
| 3-[211At]astato-α-methyl-O-methyl-L-tyrosine 211At-AAMT-O-Me-L · AAMT-O-Me-L | At-211 | Therapy | L-type amino acid transporter 1 (LAT1); developed from a seed compound (3-[211At]astato-α-methyl-L-tyrosine, 211At-AAMT-OH-L) by replacing the phenol OH with a methyl group, which increased tumour retention | preclinical | |
| 6-[18F]fluoro-3-(pyridin-3-yl)-1H-indole 6-[18F]fluoro-3-(pyridin-3-yl)-1H-indole | F-18 | PET | Tryptophan 2,3-dioxygenase (TDO) | preclinical | |
| [11C]pbb3 [11C]PBB3 · [C-11]PBB3 · C-11 PBB3 | C-11 | PET | Tau pathology / tau aggregates | — | |
| [123I]R91150 [123I]R91150 · [I-123]R91150 | I-123 | SPECT | 5-HT2A receptor | — | |
| [125I]FC-131 [125I]FC-131 · [I-125]FC-131 | I-125 | Preclinical (I-125) | CXCR4 | — | |
| [125I]Pentixafor [125I]CPCR4 · [I-125]CPCR4 · PENTIXAFOR | I-125 | Preclinical (I-125) | — | — | |
| [131I]FAPI I-131-FAPI | I-131 | Therapy | — | — | |
| [131I]I-131-Lym-1 I-131-Lym-1 | I-131 | Therapy | Lym-1 antibody target (HLA-DR-like B-cell surface antigen) | — | |
| [153Sm]Sm-BPAMD Sm-153-BPAMD | Sm-153 | Therapy | bone surface (hydroxyapatite mineral binding via bisphosphonate) | preclinical | |
| [153Sm]Sm-DOTATATE DOTATATE · DOTA-TATE · dotatate | Sm-153 | Therapy | — | — | |
| [169Er]Er-PSMA-617 PSMA-617 · Pluvicto | Er-169 | Therapy | — | — | |
| [177Lu]Lu-(R)-DOTAGA-rhCCK-1 [177Lu]Lu-(R)-DOTAGA-rhCCK-1 · [Lu-177]Lu-(R)-DOTAGA-rhCCK-1 | Lu-177 | Therapy | — | — | |
| [177Lu]Lu-CHX-A [Lu-177]Lu-CHX-A | Lu-177 | Therapy | — | — | |
| [177Lu]Lu-DOTA-FAPI-04 [Lu-177]Lu-DOTA-FAPI-04 | Lu-177 | Therapy | — | — | |
| [177Lu]Lu-DTPA-anti-TRA [Lu-177]Lu-DTPA-anti-TRA | Lu-177 | Therapy | TRA-1-60, a cancer stemness marker | preclinical | |
| [177Lu]Lu-Evans [Lu-177]Lu-Evans | Lu-177 | Therapy | Fibroblast activation protein (FAP) | investigational | |
| [177Lu]Lu-OncoFAP OncoFAP · Lu-177-OncoFAP | Lu-177 | Therapy | Fibroblast activation protein (FAP) | preclinical | |
| [177Lu]Lu-OncoFAP-DOTAGA [177Lu]Lu-OncoFAP-DOTAGA | Lu-177 | Therapy | FAP | Research | |
| [177Lu]Lu-PSMA-617-treated Lu-177-PSMA-617-treated · [Lu-177]Lu-PSMA-617-treated | Lu-177 | Therapy | Prostate-specific membrane antigen (PSMA) | investigational | |
| [177Lu]Lu-rhPSMA-10 [177Lu]Lu-rhPSMA-10 · [Lu-177]Lu-rhPSMA-10 | Lu-177 | Therapy | prostate-specific membrane antigen (PSMA) | phase I | |
| [188Re]Re-188-HYNIC-Bombesin Re-188-HYNIC-Bombesin · Re-188-Hynic-Bombesin | Re-188 | Therapy | — | — | |
| [188Re]Re-CpTR-COOH [Re-188]CpTR-COOH | Re-188 | Therapy | — | — | |
| [188Re]Re-RC-160 Re-188-RC-160 | Re-188 | Therapy | Somatostatin receptor targeting via octreotide | — | |
| [18F]AH113804 [18F]AH113804 · [F-18]AH113804 · AH113804 | F-18 | PET | c-Met (hepatocyte growth factor receptor); peptide-based agent with high affinity for human c-Met | Research | |
| [18F]AlF-OncoFAP [18F]AlF-OncoFAP · [F-18]AlF-OncoFAP | F-18 | PET | FAP (fibroblast activation protein) | — | |
| [18F]AlF-OncoFAP-NODAGA [18F]AlF-OncoFAP-NODAGA · [F-18]AlF-OncoFAP-NODAGA | F-18 | PET | FAP | Research | |
| [18F]AlF-OncoFAP-NOTA [18F]AlF-OncoFAP-NOTA · [F-18]AlF-OncoFAP-NOTA | F-18 | PET | FAP | Research | |
| [18F]F-Py-TFP 6-[18F]fluoronicotinic acid 2,3,5,6-tetrafluorophenyl ester · 6-[18F]fluoronicotinic acid tetrafluorophenyl ester · [18F]F-Py-TFP | F-18 | n/a | n/a | n/a | |
| [18F]FB-4AH29 [18F]FB-4AH29 · [F-18]FB-4AH29 | F-18 | PET | Fibroblast activation protein-α (FAP-α) | preclinical | |
| [18F]FBNA [18F]FBNA | F-18 | PET | Bioreductive trapping in hypoxic tissue associated with HIF-1α expression (2-nitroimidazole hypoxia marker) | preclinical | |
| [18F]FE-DPN [18F]FE-DPN · [18F]fluoroethyldiprenorphine · [F-18]FE-DPN | F-18 | PET | Mu opioid receptor (MOR) / opioid receptors | — | |
| [18F]FP-ERGDySO3 [18F]FP-ERGDySO3 · [F-18]FP-ERGDySO3 | F-18 | PET | — | — | |
| [18F]FP-cRGDySO3 [18F]FP-cRGDySO3 · [F-18]FP-cRGDySO3 | F-18 | PET | — | — | |
| [18F]FRPG (R)-4-(3-[18F]fluoropropyl)-L-glutamic acid · [18F]FRPG · [F-18]FRPG | F-18 | PET | (R)-stereoisomer of FSPG; evaluated for recognition by the cystine/glutamate antiporter (system xc-) | Research | |
| [18F]FSO3-PSMA [18F]FSO3-PSMA · [F-18]FSO3-PSMA | F-18 | PET | Prostate-specific membrane antigen (PSMA); PSMA ligand bearing an aryl fluorosulfate (-OSO2F) group labelled by 18F/19F sulfur-fluoride exchange (SuFEx) | Research | |
| [18F]Fluciclatide [18F]AH111585 · [18F]Fluciclatide · [F-18]AH111585 | F-18 | PET | Integrin alpha-v beta-3 (RGD peptide); marker of angiogenesis | Research | |
| [18F]FluorThanatrace [18F]FluorThanatrace · [F-18]FluorThanatrace | F-18 | PET | Poly(ADP-ribose) polymerase-1 (PARP-1) enzyme | — | |
| [18F]GTP1 [18F]GTP1 | F-18 | PET | Tau neurofibrillary tangles/paired-helical filaments | — | |
| [18F]L-Glutamic [18F]L-Glutamic · [F-18]L-Glutamic · F-18 L-Glutamic | F-18 | PET | cystine/glutamate antiporter, system xc- | investigational | |
| [18F]L-tryptophan [18F]L-tryptophan · [18F]Tryptophan · [F-18]L-tryptophan | F-18 | PET | — | — | |
| [18F]PEG4-1-thiol F-18 PEG4-1-thiol · F-18-PEG4-1-thiol · PEG4-1-thiol | F-18 | PET | — | — | |
| [18F]RSO2CF2H [18F]difluoromethyl heteroaryl sulfones · [18F]RSO2CF2H · [F-18]RSO2CF2H | F-18 | PET | Not a target-directed tracer - a reagent/prosthetic class ([18F]difluoromethyl aryl/heteroaryl sulfones) enabling direct 18F-difluoromethylation / [18F]difluorocarbene transfer for PET tracer synthesis | Research | |
| [18F]SO2F2 [18F]SO2F2 · [F-18]SO2F2 | F-18 | PET | — | — | |
| [18F]SqFLT 3'-[18F]fluorothymidine-5'-squaryl · [18F]SqFLT · [F-18]SqFLT | F-18 | PET | Thymidylate kinase (TMPK) - bioisostere of [18F]FLT-5'-monophosphate designed to image TMPK activity downstream of, and independent of, thymidine kinase 1 (TK1); enters cells by passive diffusion (not via nucleoside transporters) | Research | |
| [18F]VM4-037 [18F]VM4-037 · [F-18]VM4-037 · VM4-037 | F-18 | PET | Carbonic anhydrase IX (CAIX) | Research | |
| [18F]bromofluoromethane-d2 [18F]bromofluoromethane-d2 · [F-18]bromofluoromethane-d2 | F-18 | PET | — | — | |
| [18F]ef5 [18F]EF-5 · [F-18]EF-5 · EF5 | F-18 | PET | Bioreductive trapping via nitroreductase-mediated metabolism under low oxygen tension (hypoxia marker) | — | |
| [18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine [18F]Fluoro-3-(2(S)-azetidinylmethoxy)pyridine · [F-18]Fluoro-3-(2(S)-azetidinylmethoxy)pyridine | F-18 | PET | α4β2* nicotinic acetylcholine receptors (nAChRs) | — | |
| [18F]fluoroethylazide [18F]fluoroethylazide · [F-18]fluoroethylazide | F-18 | PET | — | — | |
| [18F]fluorogabapentin [18F]Fluorogabapentin · [F-18]Fluorogabapentin | F-18 | PET | α2δ subunit of voltage-dependent calcium channels | preclinical | |
| [18F]fluoromethyl tosylate [18F]fluoromethyl tosylate | F-18 | n/a | n/a | n/a | |
| [18F]fluorophenylalanine [18F]Fluorophenylalanine · [F-18]Fluorophenylalanine | F-18 | PET | L-type amino acid transporter 1 (LAT1) | first-in-human | |
| [18F]pi2620 [18F]PI-2620 · [18F]PI2620 · [F-18]PI-2620 | F-18 | PET | Tau aggregates (second-generation tau PET tracer, including 4R tauopathy tau) | — | |
| [18F]ro948 [18F]RO-948 · [F-18]RO-948 | F-18 | PET | Tau neurofibrillary tangles / paired helical filament tau aggregates | — | |
| [211At]At-astatinated [At-211]astatinated · [At-211]Astatinated | At-211 | Therapy | Prostate-specific membrane antigen (PSMA) | — | |
| [212Pb]Pb-212-F3-C25 Pb-212-F3-C25 | Pb-212 | Therapy | — | — | |
| [213Bi]Bi-DOTA-TOC DOTATOC · DOTA-TOC | Bi-213 | Therapy | — | — | |
| [225Ac]Ac-DOTA-TOC DOTATOC · DOTA-TOC | Ac-225 | Therapy | — | — | |
| [225Ac]Ac-SibuDAB [Ac-225]Ac-SibuDAB | Ac-225 | Therapy | Prostate-specific membrane antigen (PSMA) | investigational | |
| [225Ac]Ac-crown-TATE [Ac-225]Ac-crown-TATE | Ac-225 | Therapy | Somatostatin receptor 2 (SSTR2) | — | |
| [225Ac]Ac-mcp-IgG4 [Ac-225]Ac-mcp-IgG4 | Ac-225 | Therapy | — | Reported once | |
| [47Sc]Sc-DOTA-TOC DOTATOC · DOTA-TOC | Sc-47 | Therapy | — | — | |
| [47Sc]Sc-DOTANOC DOTANOC · Sc-47-DOTANOC | Sc-47 | Therapy | — | — | |
| [47Sc]Sc-FAPI Sc-47-FAPI | Sc-47 | Therapy | — | — | |
| [67Cu]Cu-FAPI-2286 [Cu-67]Cu-FAPI-2286 | Cu-67 | Therapy | Fibroblast Activation Protein (FAP) | — | |
| [68Ga]Ga-DOTA-AMBS-CPCR4 [68Ga]DOTA-AMBS-CPCR4 · [Ga-68]DOTA-AMBS-CPCR4 | Ga-68 | PET | CXCR4 | — | |
| [68Ga]Ga-DOTA-Arg3-Nal4-Gly5 [68Ga]DOTA-Arg3-Nal4-Gly5 · [Ga-68]DOTA-Arg3-Nal4-Gly5 | Ga-68 | PET | — | — | |
| [68Ga]Ga-FAPI-02 [68Ga]Ga-FAPI-02 · [Ga-68]Ga-FAPI-02 | Ga-68 | PET | Fibroblast activation protein (FAP) | — | |
| [68Ga]Ga-FAPI-64 [68Ga]Ga-FAPI-64 · [Ga-68]Ga-FAPI-64 | Ga-68 | PET | — | — | |
| [68Ga]Ga-FAPI-74 FAPI-74 · Ga-68 FAPI-74 | Ga-68 | PET | Fibroblast activation protein (FAP) | — | |
| [68Ga]Ga-OncoFAP [68Ga]Ga-OncoFAP · [Ga-68]Ga-OncoFAP · Ga-68 OncoFAP | Ga-68 | PET | — | — | |
| [68Ga]Ga-OncoFAP-NODAGA [68Ga]Ga-OncoFAP-NODAGA · [Ga-68]Ga-OncoFAP-NODAGA | Ga-68 | PET | FAP | Research | |
| [68Ga]Ga-OncoFAP-NOTA [68Ga]Ga-OncoFAP-NOTA · [Ga-68]Ga-OncoFAP-NOTA | Ga-68 | PET | FAP | Research | |
| [89Zr]Zr-Df-IgG-800CW Df-IgG-800CW · Zr-89 Df-IgG-800CW · Zr-89-Df-IgG-800CW | Zr-89 | PET | — | — | |
| [99mTc]Tc-N4-Bombesin [99mTc]Tc-N4-Bombesin · [Tc-99m]Tc-N4-Bombesin | Tc-99m | SPECT | — | — |